



US010632313B2

(12) **United States Patent**  
**Juffer et al.**

(10) **Patent No.:** **US 10,632,313 B2**  
(45) **Date of Patent:** **Apr. 28, 2020**

(54) **SYSTEMS, DEVICES, AND METHODS FOR SETTING CARDIAC PACING PULSE PARAMETERS FOR A CARDIAC PACING DEVICE**

(58) **Field of Classification Search**  
CPC ... A61N 1/371; A61N 1/3712; A61N 1/37247  
See application file for complete search history.

(71) Applicant: **CARDIAC PACEMAKERS, INC.**, St. Paul, MN (US)

(56) **References Cited**

U.S. PATENT DOCUMENTS

(72) Inventors: **Lance Eric Juffer**, Lino Lakes, MN (US); **William J. Linder**, Golden Valley, MN (US); **Ron A. Balczewski**, Bloomington, MN (US); **Keith R. Maile**, New Brighton, MN (US)

3,835,864 A 9/1974 Rasor et al.  
3,943,936 A 3/1976 Rasor et al.  
(Continued)

(73) Assignee: **CARDIAC PACEMAKERS, INC.**, St. Paul, MN (US)

FOREIGN PATENT DOCUMENTS

AU 2008279789 B2 10/2011  
AU 2008329620 B2 5/2014  
(Continued)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 173 days.

OTHER PUBLICATIONS

US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn)  
(Continued)

(21) Appl. No.: **15/804,699**

*Primary Examiner* — Joseph M Dietrich

(22) Filed: **Nov. 6, 2017**

(74) *Attorney, Agent, or Firm* — Seager, Tufte & Wickhem LLP

(65) **Prior Publication Data**

US 2018/0126174 A1 May 10, 2018

(57) **ABSTRACT**

**Related U.S. Application Data**

(60) Provisional application No. 62/419,731, filed on Nov. 9, 2016.

Systems, devices, and methods for pacing a heart of a patient are disclosed. A device may include a leadless cardiac pacemaker (LCP) that includes a power supply, a pair of electrodes, and a controller operably connected to the electrodes and the power supply. The controller may identify a capture threshold by setting a pace amplitude at a power supply voltage of the power supply and deliver pacing stimulation pulses with different pulse widths to identify the capture threshold. The LCP may then deliver pacing stimulation pulses based, at least in part, on a pulse amplitude and pulse width associated with the capture threshold, and also adding a capture margin. In some cases, the pulse amplitude may change over time and the LCP may adjust a pulse width along a strength-duration curve to account for the pulse amplitude change and maintain a capture threshold and capture margin.


(51) **Int. Cl.**

*A61N 1/37* (2006.01)  
*A61N 1/375* (2006.01)  
*A61N 1/372* (2006.01)  
*A61N 1/378* (2006.01)

(52) **U.S. Cl.**

CPC ..... *A61N 1/3712* (2013.01); *A61N 1/371* (2013.01); *A61N 1/378* (2013.01); *A61N 1/3756* (2013.01); *A61N 1/37247* (2013.01); *A61N 1/37512* (2017.08); *A61N 1/3708* (2013.01)

**20 Claims, 12 Drawing Sheets**



(56)

## References Cited

## U.S. PATENT DOCUMENTS

4,142,530 A	3/1979	Wittkampf	5,383,915 A	1/1995	Adams
4,151,513 A	4/1979	Menken et al.	5,388,578 A	2/1995	Yomtov et al.
4,157,720 A	6/1979	Greatbatch	5,404,877 A	4/1995	Nolan et al.
RE30,366 E	8/1980	Rasor et al.	5,405,367 A	4/1995	Schulman et al.
4,243,045 A	1/1981	Maas	5,411,031 A	5/1995	Yomtov
4,250,884 A	2/1981	Hartlaub et al.	5,411,525 A	5/1995	Swanson et al.
4,256,115 A	3/1981	Bilitch	5,411,533 A	5/1995	Dubreuil et al.
4,263,919 A	4/1981	Levin	5,411,535 A	5/1995	Fujii et al.
4,278,094 A	7/1981	Zobel	5,447,525 A	9/1995	Powell et al.
4,310,000 A	1/1982	Lindemans	5,456,691 A	10/1995	Snell
4,312,354 A	1/1982	Walters	5,458,622 A	10/1995	Alt
4,323,081 A	4/1982	Wiebusch	5,466,246 A	11/1995	Silvian
4,357,946 A	11/1982	Dutcher et al.	5,468,254 A	11/1995	Hahn et al.
4,365,639 A	12/1982	Goldreyer	5,472,453 A	12/1995	Alt
4,440,173 A	4/1984	Hudziak et al.	5,522,866 A	6/1996	Fernald
4,476,868 A	10/1984	Thompson	5,540,727 A	7/1996	Tockman et al.
4,522,208 A	6/1985	Buffet	5,545,186 A	8/1996	Olson et al.
4,537,200 A	8/1985	Widrow	5,545,202 A	8/1996	Dahl et al.
4,556,063 A	12/1985	Thompson et al.	5,571,146 A	11/1996	Jones et al.
4,562,841 A	1/1986	Brockway et al.	5,591,214 A	1/1997	Lu
4,593,702 A	6/1986	Kepski et al.	5,620,466 A	4/1997	Haefner et al.
4,593,955 A	6/1986	Leiber	5,634,938 A	6/1997	Swanson et al.
4,630,611 A	12/1986	King	5,649,968 A	7/1997	Alt et al.
4,635,639 A	1/1987	Hakala et al.	5,662,688 A	9/1997	Haefner et al.
4,674,508 A	6/1987	DeCote	5,674,259 A	10/1997	Gray
4,712,554 A	12/1987	Garson	5,683,426 A	11/1997	Greenhut et al.
4,729,376 A	3/1988	DeCote	5,683,432 A	11/1997	Goedeke et al.
4,754,753 A	7/1988	King	5,706,823 A	1/1998	Wodlinger
4,759,366 A	7/1988	Callaghan	5,709,215 A	1/1998	Perttu et al.
4,776,338 A	10/1988	Lekholm et al.	5,720,770 A	2/1998	Nappholz et al.
4,787,389 A	11/1988	Tarjan	5,728,154 A	3/1998	Crossett et al.
4,793,353 A	12/1988	Borkan	5,741,314 A	4/1998	Daly et al.
4,819,662 A	4/1989	Heil et al.	5,741,315 A	4/1998	Lee et al.
4,858,610 A	8/1989	Callaghan et al.	5,752,976 A	5/1998	Duffin et al.
4,886,064 A	12/1989	Strandberg	5,752,977 A	5/1998	Grevious et al.
4,887,609 A	12/1989	Cole	5,755,736 A	5/1998	Gillberg et al.
4,928,688 A	5/1990	Mower	5,759,199 A	6/1998	Snell et al.
4,967,746 A	11/1990	Vandegriff	5,774,501 A	6/1998	Halpern et al.
4,987,897 A	1/1991	Funke	5,792,195 A	8/1998	Carlson et al.
4,989,602 A	2/1991	Sholder et al.	5,792,202 A	8/1998	Rueter
5,012,806 A	5/1991	De Bellis	5,792,203 A	8/1998	Schroepel
5,036,849 A	8/1991	Hauck et al.	5,792,205 A	8/1998	Alt et al.
5,040,534 A	8/1991	Mann et al.	5,792,208 A	8/1998	Gray
5,058,581 A	10/1991	Silvian	5,814,089 A	9/1998	Stokes et al.
5,078,134 A	1/1992	Heilman et al.	5,827,216 A	10/1998	Igo et al.
5,109,845 A	5/1992	Yuuchi et al.	5,836,985 A	11/1998	Rostami et al.
5,113,859 A	5/1992	Funke	5,836,987 A	11/1998	Baumann et al.
5,113,869 A	5/1992	Nappholz et al.	5,842,977 A	12/1998	Lesho et al.
5,117,824 A	6/1992	Keimel et al.	5,843,136 A	12/1998	Zhu et al.
5,127,401 A	7/1992	Grevious et al.	5,855,593 A	1/1999	Olson et al.
5,133,353 A	7/1992	Hauser	5,873,894 A	2/1999	Vandegriff et al.
5,144,950 A	9/1992	Stoop et al.	5,891,184 A	4/1999	Lee et al.
5,170,784 A	12/1992	Ramon et al.	5,897,586 A	4/1999	Molina
5,179,945 A	1/1993	Van Hofwegen et al.	5,899,876 A	5/1999	Flower
5,193,539 A	3/1993	Schulman et al.	5,899,928 A	5/1999	Sholder et al.
5,193,540 A	3/1993	Schulman et al.	5,919,214 A	7/1999	Ciciarelli et al.
5,241,961 A	9/1993	Henry	5,935,078 A	8/1999	Feierbach
5,243,977 A	9/1993	Trabucco et al.	5,941,906 A	8/1999	Barreras, Sr. et al.
5,259,387 A	11/1993	DePinto	5,944,744 A	8/1999	Paul et al.
5,269,326 A	12/1993	Verrier	5,948,004 A	9/1999	Weijand et al.
5,284,136 A	2/1994	Hauck et al.	5,954,757 A	9/1999	Gray
5,300,107 A	4/1994	Stokes et al.	5,978,713 A	11/1999	Prutchi et al.
5,301,677 A	4/1994	Hsung	5,991,660 A	11/1999	Goyal
5,305,760 A	4/1994	McKown et al.	5,991,661 A	11/1999	Park et al.
5,312,439 A	5/1994	Loeb	5,999,848 A	12/1999	Gord et al.
5,313,953 A	5/1994	Yomtov et al.	5,999,857 A	12/1999	Weijand et al.
5,314,459 A	5/1994	Swanson et al.	6,016,445 A	1/2000	Baura
5,318,597 A	6/1994	Hauck et al.	6,026,320 A	2/2000	Carlson et al.
5,324,316 A	6/1994	Schulman et al.	6,029,085 A	2/2000	Olson et al.
5,331,966 A	7/1994	Bennett et al.	6,041,250 A	3/2000	DePinto
5,334,222 A	8/1994	Salo et al.	6,044,298 A	3/2000	Salo et al.
5,342,408 A	8/1994	deCoriolis et al.	6,044,300 A	3/2000	Gray
5,370,667 A	12/1994	Alt	6,055,454 A	4/2000	Heemels
5,372,606 A	12/1994	Lang et al.	6,073,050 A	6/2000	Griffith
5,376,106 A	12/1994	Stahmann et al.	6,076,016 A	6/2000	Feierbach
			6,077,236 A	6/2000	Cunningham
			6,080,187 A	6/2000	Alt et al.
			6,083,248 A	7/2000	Thompson
			6,106,551 A	8/2000	Crossett et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,115,636	A	9/2000	Ryan	6,564,807	B1	5/2003	Schulman et al.
6,128,526	A	10/2000	Stadler et al.	6,574,506	B2	6/2003	Kramer et al.
6,141,581	A	10/2000	Olson et al.	6,584,351	B1	6/2003	Ekwall
6,141,588	A	10/2000	Cox et al.	6,584,352	B2	6/2003	Combs et al.
6,141,592	A	10/2000	Pauly	6,597,948	B1	7/2003	Rockwell et al.
6,144,879	A	11/2000	Gray	6,597,951	B2	7/2003	Kramer et al.
6,162,195	A	12/2000	Igo et al.	6,622,046	B2	9/2003	Fraley et al.
6,164,284	A	12/2000	Schulman et al.	6,628,985	B2	9/2003	Sweeney et al.
6,167,310	A	12/2000	Grevious	6,647,292	B1	11/2003	Bardy et al.
6,201,993	B1	3/2001	Kruse et al.	6,666,844	B1	12/2003	Igo et al.
6,208,894	B1	3/2001	Schulman et al.	6,689,117	B2	2/2004	Sweeney et al.
6,211,799	B1	4/2001	Post et al.	6,690,959	B2	2/2004	Thompson
6,221,011	B1	4/2001	Bardy	6,694,189	B2	2/2004	Begemann
6,240,316	B1	5/2001	Richmond et al.	6,704,602	B2	3/2004	Berg et al.
6,240,317	B1	5/2001	Villaseca et al.	6,718,212	B2	4/2004	Parry et al.
6,256,534	B1	7/2001	Dahl	6,721,597	B1	4/2004	Bardy et al.
6,259,947	B1	7/2001	Olson et al.	6,738,668	B1	5/2004	Mouchawar et al.
6,266,558	B1	7/2001	Gozani et al.	6,738,670	B1	5/2004	Almendinger et al.
6,266,567	B1	7/2001	Ishikawa et al.	6,746,797	B2	6/2004	Benson et al.
6,270,457	B1	8/2001	Bardy	6,749,566	B2	6/2004	Russ
6,272,377	B1	8/2001	Sweeney et al.	6,758,810	B2	7/2004	Lebel et al.
6,273,856	B1	8/2001	Sun et al.	6,763,269	B2	7/2004	Cox
6,277,072	B1	8/2001	Bardy	6,778,860	B2	8/2004	Ostroff et al.
6,280,380	B1	8/2001	Bardy	6,788,971	B1	9/2004	Sloman et al.
6,285,907	B1	9/2001	Kramer et al.	6,788,974	B2	9/2004	Bardy et al.
6,292,698	B1	9/2001	Duffin et al.	6,804,558	B2	10/2004	Haller et al.
6,295,473	B1	9/2001	Rosar	6,807,442	B1	10/2004	Myklebust et al.
6,297,943	B1	10/2001	Carson	6,847,844	B2	1/2005	Sun et al.
6,298,271	B1	10/2001	Weijand	6,871,095	B2	3/2005	Stahmann et al.
6,307,751	B1	10/2001	Bodony et al.	6,878,112	B2	4/2005	Linberg et al.
6,312,378	B1	11/2001	Bardy	6,885,889	B2	4/2005	Chinchoy
6,315,721	B2	11/2001	Schulman et al.	6,892,094	B2	5/2005	Ousdigian et al.
6,336,903	B1	1/2002	Bardy	6,897,788	B2	5/2005	Khair et al.
6,345,202	B2	2/2002	Richmond et al.	6,904,315	B2	6/2005	Panken et al.
6,351,667	B1	2/2002	Godie	6,922,592	B2	7/2005	Thompson et al.
6,351,669	B1	2/2002	Hartley et al.	6,931,282	B2	8/2005	Esler
6,353,759	B1	3/2002	Hartley et al.	6,934,585	B1	8/2005	Schloss et al.
6,358,203	B2	3/2002	Bardy	6,957,107	B2	10/2005	Rogers et al.
6,361,780	B1	3/2002	Ley et al.	6,978,176	B2	12/2005	Lattouf
6,368,284	B1	4/2002	Bardy	6,985,773	B2	1/2006	Von Arx et al.
6,371,922	B1	4/2002	Baumann et al.	6,990,375	B2	1/2006	Kloss et al.
6,398,728	B1	6/2002	Bardy	7,001,366	B2	2/2006	Ballard
6,400,982	B2	6/2002	Sweeney et al.	7,003,350	B2	2/2006	Denker et al.
6,400,990	B1	6/2002	Silvian	7,006,864	B2	2/2006	Echt et al.
6,408,208	B1	6/2002	Sun	7,013,178	B2	3/2006	Reinke et al.
6,409,674	B1	6/2002	Brockway et al.	7,024,246	B2	4/2006	Acosta et al.
6,411,848	B2	6/2002	Kramer et al.	7,027,871	B2	4/2006	Burnes et al.
6,424,865	B1	7/2002	Ding	7,050,849	B2	5/2006	Echt et al.
6,434,429	B1	8/2002	Kraus et al.	7,060,031	B2	6/2006	Webb et al.
6,438,410	B2	8/2002	Hsu et al.	7,063,693	B2	6/2006	Guenst
6,438,417	B1	8/2002	Rockwell et al.	7,082,336	B2	7/2006	Ransbury et al.
6,438,421	B1	8/2002	Stahmann et al.	7,085,606	B2	8/2006	Flach et al.
6,440,066	B1	8/2002	Bardy	7,092,758	B2	8/2006	Sun et al.
6,441,747	B1	8/2002	Khair et al.	7,110,824	B2	9/2006	Amundson et al.
6,442,426	B1	8/2002	Kroll	7,120,504	B2	10/2006	Osyepka
6,442,432	B2	8/2002	Lee	7,130,681	B2	10/2006	Gebhardt et al.
6,443,891	B1	9/2002	Grevious	7,139,613	B2	11/2006	Reinke et al.
6,445,953	B1	9/2002	Bulkes et al.	7,142,912	B2	11/2006	Wagner et al.
6,453,200	B1	9/2002	Koslar	7,146,225	B2	12/2006	Guenst et al.
6,459,929	B1	10/2002	Hopper et al.	7,146,226	B2	12/2006	Lau et al.
6,470,215	B1	10/2002	Kraus et al.	7,149,581	B2	12/2006	Goedeke
6,471,645	B1	10/2002	Warkentin et al.	7,149,588	B2	12/2006	Lau et al.
6,480,745	B2	11/2002	Nelson et al.	7,158,839	B2	1/2007	Lau
6,487,443	B2	11/2002	Olson et al.	7,162,307	B2	1/2007	Patrias
6,490,487	B1	12/2002	Kraus et al.	7,164,952	B2	1/2007	Lau et al.
6,498,951	B1	12/2002	Larson et al.	7,177,700	B1	2/2007	Cox
6,507,755	B1	1/2003	Gozani et al.	7,181,505	B2	2/2007	Haller et al.
6,507,759	B1	1/2003	Prutchi et al.	7,184,830	B2	2/2007	Echt et al.
6,512,940	B1	1/2003	Brabec et al.	7,186,214	B2	3/2007	Ness
6,522,915	B1	2/2003	Ceballos et al.	7,191,015	B2	3/2007	Lamson et al.
6,526,311	B2	2/2003	Begemann	7,200,437	B1	4/2007	Nabutovsky et al.
6,539,253	B2	3/2003	Thompson et al.	7,200,439	B2	4/2007	Zdeblick et al.
6,542,775	B2	4/2003	Ding et al.	7,206,423	B1	4/2007	Feng et al.
6,553,258	B2	4/2003	Stahmann et al.	7,209,785	B2	4/2007	Kim et al.
6,561,975	B1	5/2003	Pool et al.	7,209,790	B2	4/2007	Thompson et al.
				7,211,884	B1	5/2007	Davis et al.
				7,212,871	B1	5/2007	Morgan
				7,226,440	B2	6/2007	Gelfand et al.
				7,228,183	B2	6/2007	Sun et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

7,236,821 B2	6/2007	Cates et al.	7,742,822 B2	6/2010	Masoud et al.
7,236,829 B1	6/2007	Farazi et al.	7,743,151 B2	6/2010	Vallapureddy et al.
7,254,448 B2	8/2007	Almendinger et al.	7,747,335 B2	6/2010	Williams
7,260,436 B2	8/2007	Kilgore et al.	7,751,881 B2	7/2010	Cowan et al.
7,270,669 B1	9/2007	Sra	7,758,521 B2	7/2010	Morris et al.
7,272,448 B1	9/2007	Morgan et al.	7,761,150 B2	7/2010	Ghanem et al.
7,277,755 B1	10/2007	Falkenberg et al.	7,761,164 B2	7/2010	Verhoef et al.
7,280,872 B1	10/2007	Mosesov et al.	7,765,001 B2	7/2010	Echt et al.
7,288,096 B2	10/2007	Chin	7,769,452 B2	8/2010	Ghanem et al.
7,289,847 B1	10/2007	Gill et al.	7,783,362 B2	8/2010	Whitehurst et al.
7,289,852 B2	10/2007	Helfinstine et al.	7,792,588 B2	9/2010	Harding
7,289,853 B1	10/2007	Campbell et al.	7,797,059 B1	9/2010	Bornzin et al.
7,289,855 B2	10/2007	Nghiem et al.	7,801,596 B2	9/2010	Fischell et al.
7,302,294 B2	11/2007	Kamath et al.	7,809,438 B2	10/2010	Echt et al.
7,305,266 B1	12/2007	Kroll	7,840,281 B2	11/2010	Kveen et al.
7,310,556 B2	12/2007	Bulkes	7,844,331 B2	11/2010	Li et al.
7,319,905 B1	1/2008	Morgan et al.	7,844,348 B2	11/2010	Swoyer et al.
7,321,798 B2	1/2008	Muhlenberg et al.	7,846,088 B2	12/2010	Ness
7,333,853 B2	2/2008	Mazar et al.	7,848,815 B2	12/2010	Brisken et al.
7,336,994 B2	2/2008	Hettrick et al.	7,848,823 B2	12/2010	Drasler et al.
7,347,819 B2	3/2008	Lebel et al.	7,860,455 B2	12/2010	Fukumoto et al.
7,366,572 B2	4/2008	Heruth et al.	7,871,433 B2	1/2011	Lattouf
7,373,207 B2	5/2008	Lattouf	7,877,136 B1	1/2011	Moffitt et al.
7,384,403 B2	6/2008	Sherman	7,877,142 B2	1/2011	Moaddeb et al.
7,386,342 B1	6/2008	Falkenberg et al.	7,881,786 B2	2/2011	Jackson
7,392,090 B2	6/2008	Sweeney et al.	7,881,798 B2	2/2011	Miesel et al.
7,406,105 B2	7/2008	DelMain et al.	7,881,810 B1	2/2011	Chitre et al.
7,406,349 B2	7/2008	Seeberger et al.	7,890,173 B2	2/2011	Brisken et al.
7,410,497 B2	8/2008	Hastings et al.	7,890,181 B2	2/2011	Denzene et al.
7,425,200 B2	9/2008	Brockway et al.	7,890,192 B1	2/2011	Kelsch et al.
7,433,739 B1	10/2008	Salys et al.	7,894,885 B2	2/2011	Bartal et al.
7,496,409 B2	2/2009	Greenhut et al.	7,894,894 B2	2/2011	Stadler et al.
7,496,410 B2	2/2009	Heil	7,894,907 B2	2/2011	Cowan et al.
7,502,652 B2	3/2009	Gaunt et al.	7,894,910 B2	2/2011	Cowan et al.
7,512,448 B2	3/2009	Malick et al.	7,894,915 B1	2/2011	Chitre et al.
7,515,969 B2	4/2009	Tockman et al.	7,899,537 B1	3/2011	Kroll et al.
7,526,342 B2	4/2009	Chin et al.	7,899,541 B2	3/2011	Cowan et al.
7,529,589 B2	5/2009	Williams et al.	7,899,542 B2	3/2011	Cowan et al.
7,532,933 B2	5/2009	Hastings et al.	7,899,554 B2	3/2011	Williams et al.
7,536,222 B2	5/2009	Bardy et al.	7,901,360 B1	3/2011	Yang et al.
7,536,224 B2	5/2009	Ritscher et al.	7,904,170 B2	3/2011	Harding
7,539,541 B2	5/2009	Quiles et al.	7,907,993 B2	3/2011	Ghanem et al.
7,544,197 B2	6/2009	Kelsch et al.	7,920,928 B1	4/2011	Yang et al.
7,558,631 B2	7/2009	Cowan et al.	7,925,343 B1	4/2011	Min et al.
7,565,195 B1	7/2009	Kroll et al.	7,930,022 B2	4/2011	Zhang et al.
7,584,002 B2	9/2009	Burnes et al.	7,930,040 B1	4/2011	Kelsch et al.
7,590,455 B2	9/2009	Heruth et al.	7,937,135 B2	5/2011	Ghanem et al.
7,606,621 B2	10/2009	Brisken et al.	7,937,148 B2	5/2011	Jacobson
7,610,088 B2	10/2009	Chinchoy	7,937,161 B2	5/2011	Hastings et al.
7,610,092 B2	10/2009	Cowan et al.	7,941,214 B2	5/2011	Kleckner et al.
7,610,099 B2	10/2009	Almendinger et al.	7,945,333 B2	5/2011	Jacobson
7,610,104 B2	10/2009	Kaplan et al.	7,946,997 B2	5/2011	Hübinette
7,616,991 B2	11/2009	Mann et al.	7,949,404 B2	5/2011	Hill
7,617,001 B2	11/2009	Penner et al.	7,949,405 B2	5/2011	Feher
7,617,007 B2	11/2009	Williams et al.	7,953,486 B2	5/2011	Daum et al.
7,630,767 B1	12/2009	Poore et al.	7,953,493 B2	5/2011	Fowler et al.
7,634,313 B1	12/2009	Kroll et al.	7,962,202 B2	6/2011	Bhunja
7,637,867 B2	12/2009	Zdeblick	7,974,702 B1	7/2011	Fain et al.
7,640,060 B2	12/2009	Zdeblick	7,979,136 B2	7/2011	Young et al.
7,647,109 B2	1/2010	Hastings et al.	7,983,753 B2	7/2011	Severin
7,650,186 B2	1/2010	Hastings et al.	7,991,467 B2	8/2011	Markowitz et al.
7,657,311 B2	2/2010	Bardy et al.	7,991,471 B2	8/2011	Ghanem et al.
7,668,596 B2	2/2010	Von Arx et al.	7,996,087 B2	8/2011	Cowan et al.
7,682,316 B2	3/2010	Anderson et al.	8,000,791 B2	8/2011	Sunagawa et al.
7,691,047 B2	4/2010	Ferrari	8,000,807 B2	8/2011	Morris et al.
7,702,392 B2	4/2010	Echt et al.	8,001,975 B2	8/2011	DiSilvestro et al.
7,713,194 B2	5/2010	Zdeblick	8,002,700 B2	8/2011	Ferek-Petric et al.
7,713,195 B2	5/2010	Zdeblick	8,010,209 B2	8/2011	Jacobson
7,729,783 B2	6/2010	Michels et al.	8,019,419 B1	9/2011	Panescu et al.
7,734,333 B2	6/2010	Ghanem et al.	8,019,434 B2	9/2011	Quiles et al.
7,734,343 B2	6/2010	Ransbury et al.	8,027,727 B2	9/2011	Freeberg
7,738,958 B2	6/2010	Zdeblick et al.	8,027,729 B2	9/2011	Sunagawa et al.
7,738,964 B2	6/2010	Von Arx et al.	8,032,219 B2	10/2011	Neumann et al.
7,742,812 B2	6/2010	Ghanem et al.	8,036,743 B2	10/2011	Savage et al.
7,742,816 B2	6/2010	Masoud et al.	8,046,079 B2	10/2011	Bange et al.
			8,046,080 B2	10/2011	Von Arx et al.
			8,050,297 B2	11/2011	DelMain et al.
			8,050,759 B2	11/2011	Stegemann et al.
			8,050,774 B2	11/2011	Kveen et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

8,055,345 B2	11/2011	Li et al.	8,433,420 B2	4/2013	Bange et al.
8,055,350 B2	11/2011	Roberts	8,446,212 B2	5/2013	Tranchina et al.
8,060,212 B1	11/2011	Rios et al.	8,447,412 B2	5/2013	Dal Molin et al.
8,065,018 B2	11/2011	Haubrich et al.	8,452,413 B2	5/2013	Young et al.
8,073,542 B2	12/2011	Doerr	8,457,740 B2	6/2013	Osche
8,078,278 B2	12/2011	Penner	8,457,742 B2	6/2013	Jacobson
8,078,283 B2	12/2011	Cowan et al.	8,457,744 B2	6/2013	Janzig et al.
8,095,123 B2	1/2012	Gray	8,457,761 B2	6/2013	Wariar
8,102,789 B2	1/2012	Rosar et al.	8,478,407 B2	7/2013	Demmer et al.
8,103,359 B2	1/2012	Reddy	8,478,408 B2	7/2013	Hastings et al.
8,103,361 B2	1/2012	Moser	8,478,431 B2	7/2013	Griswold et al.
8,112,148 B2	2/2012	Giftakis et al.	8,494,632 B2	7/2013	Sun et al.
8,114,021 B2	2/2012	Robertson et al.	8,504,156 B2	8/2013	Bonner et al.
8,121,680 B2	2/2012	Falkenberg et al.	8,509,910 B2	8/2013	Sowder et al.
8,123,684 B2	2/2012	Zdeblick	8,515,559 B2	8/2013	Roberts et al.
8,126,545 B2	2/2012	Flach et al.	8,525,340 B2	9/2013	Eckhardt et al.
8,131,334 B2	3/2012	Lu et al.	8,527,068 B2	9/2013	Ostroff
8,140,161 B2	3/2012	Willerton et al.	8,532,790 B2	9/2013	Griswold
8,150,521 B2	4/2012	Crowley et al.	8,538,526 B2	9/2013	Stahmann et al.
8,160,672 B2	4/2012	Kim et al.	8,541,131 B2	9/2013	Lund et al.
8,160,702 B2	4/2012	Mann et al.	8,543,205 B2	9/2013	Ostroff
8,160,704 B2	4/2012	Freeberg	8,547,248 B2	10/2013	Zdeblick et al.
8,165,694 B2	4/2012	Carbanaru et al.	8,548,605 B2	10/2013	Ollivier
8,175,715 B1	5/2012	Cox	8,554,333 B2	10/2013	Wu et al.
8,180,451 B2	5/2012	Hickman et al.	8,565,882 B2	10/2013	Matos
8,185,213 B2	5/2012	Kveen et al.	8,565,897 B2	10/2013	Regnier et al.
8,187,161 B2	5/2012	Li et al.	8,571,678 B2	10/2013	Wang
8,195,293 B2	6/2012	Limousin et al.	8,577,327 B2	11/2013	Makdissi et al.
8,204,595 B2	6/2012	Pianca et al.	8,588,926 B2	11/2013	Moore et al.
8,204,605 B2	6/2012	Hastings et al.	8,612,002 B2	12/2013	Faltys et al.
8,209,014 B2	6/2012	Doerr	8,615,310 B2	12/2013	Khairkhahan et al.
8,214,043 B2	7/2012	Mates	8,626,280 B2	1/2014	Allavatam et al.
8,224,244 B2	7/2012	Kim et al.	8,626,294 B2	1/2014	Sheldon et al.
8,229,556 B2	7/2012	Li	8,634,908 B2	1/2014	Cowan
8,233,985 B2	7/2012	Bulkes et al.	8,634,912 B2	1/2014	Bornzin et al.
8,262,578 B1	9/2012	Bharmi et al.	8,634,919 B1	1/2014	Hou et al.
8,265,748 B2	9/2012	Liu et al.	8,639,335 B2	1/2014	Peichel et al.
8,265,757 B2	9/2012	Mass et al.	8,644,934 B2	2/2014	Hastings et al.
8,280,521 B2	10/2012	Haubrich et al.	8,649,859 B2	2/2014	Smith et al.
8,285,387 B2	10/2012	Utsi et al.	8,670,842 B1	3/2014	Bornzin et al.
8,290,598 B2	10/2012	Boon et al.	8,676,319 B2	3/2014	Knoll
8,290,600 B2	10/2012	Hastings et al.	8,676,335 B2	3/2014	Katoozi et al.
8,295,939 B2	10/2012	Jacobson	8,700,173 B2	4/2014	Edlund
8,301,254 B2	10/2012	Mosesov et al.	8,700,181 B2	4/2014	Bornzin et al.
8,315,701 B2	11/2012	Cowan et al.	8,705,599 B2	4/2014	dal Molin et al.
8,315,708 B2	11/2012	Berthelsdorf et al.	8,718,766 B2	5/2014	Wahlberg
8,321,021 B2	11/2012	Kisker et al.	8,718,773 B2	5/2014	Willis et al.
8,321,036 B2	11/2012	Brockway et al.	8,725,260 B2	5/2014	Shuros et al.
8,332,036 B2	12/2012	Hastings et al.	8,738,133 B2	5/2014	Shuros et al.
8,335,563 B2	12/2012	Stessman	8,738,147 B2	5/2014	Hastings et al.
8,335,568 B2	12/2012	Heruth et al.	8,744,555 B2	6/2014	Allavatam et al.
8,340,750 B2	12/2012	Prakash et al.	8,744,572 B1	6/2014	Greenhut et al.
8,340,780 B2	12/2012	Hastings et al.	8,747,314 B2	6/2014	Stahmann et al.
8,352,025 B2	1/2013	Jacobson	8,755,884 B2	6/2014	Demmer et al.
8,352,028 B2	1/2013	Wenger	8,758,365 B2	6/2014	Bonner et al.
8,352,038 B2	1/2013	Mao et al.	8,768,483 B2	7/2014	Schmitt et al.
8,359,098 B2	1/2013	Lund et al.	8,774,572 B2	7/2014	Hamamoto
8,364,261 B2	1/2013	Stubbs et al.	8,781,605 B2	7/2014	Bornzin et al.
8,364,276 B2	1/2013	Willis	8,788,035 B2	7/2014	Jacobson
8,369,959 B2	2/2013	Meskens	8,788,053 B2	7/2014	Jacobson
8,369,962 B2	2/2013	Abrahamson	8,798,740 B2	8/2014	Samade et al.
8,380,320 B2	2/2013	Spital	8,798,745 B2	8/2014	Jacobson
8,386,051 B2	2/2013	Rys	8,798,762 B2	8/2014	Fain et al.
8,391,981 B2	3/2013	Mosesov	8,798,770 B2	8/2014	Reddy
8,391,990 B2	3/2013	Smith et al.	8,805,505 B1	8/2014	Roberts
8,406,874 B2	3/2013	Liu et al.	8,805,528 B2	8/2014	Corndorf
8,406,879 B2	3/2013	Shuros et al.	8,812,109 B2	8/2014	Blomqvist et al.
8,406,886 B2	3/2013	Gaunt et al.	8,818,504 B2	8/2014	Bodner et al.
8,412,352 B2	4/2013	Griswold et al.	8,827,913 B2	9/2014	Havel et al.
8,417,340 B2	4/2013	Goossen	8,831,747 B1	9/2014	Min et al.
8,417,341 B2	4/2013	Freeberg	8,855,789 B2	10/2014	Jacobson
8,423,149 B2	4/2013	Hennig	8,868,186 B2	10/2014	Kroll
8,428,722 B2	4/2013	Verhoef et al.	8,886,339 B2	11/2014	Faltys et al.
8,433,402 B2	4/2013	Ruben et al.	8,903,473 B2	12/2014	Rogers et al.
8,433,409 B2	4/2013	Johnson et al.	8,903,500 B2	12/2014	Smith et al.
			8,903,513 B2	12/2014	Ollivier
			8,909,336 B2	12/2014	Navarro-Paredes et al.
			8,914,131 B2	12/2014	Bornzin et al.
			8,923,795 B2	12/2014	Makdissi et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

8,923,963 B2	12/2014	Bonner et al.	9,687,654 B2	6/2017	Sheldon et al.
8,938,300 B2	1/2015	Rosero	9,687,655 B2	6/2017	Pertijs et al.
8,942,806 B2	1/2015	Sheldon et al.	9,687,659 B2	6/2017	Von Arx et al.
8,958,892 B2	2/2015	Khairkhahan et al.	9,694,186 B2	7/2017	Carney et al.
8,977,358 B2	3/2015	Ewert et al.	9,782,594 B2	10/2017	Stahmann et al.
8,989,873 B2	3/2015	Locsin	9,782,601 B2	10/2017	Ludwig
8,996,109 B2	3/2015	Karst et al.	9,789,317 B2	10/2017	Greenhut et al.
9,002,467 B2	4/2015	Smith et al.	9,789,319 B2	10/2017	Sambelashvili
9,008,776 B2	4/2015	Cowan et al.	9,808,617 B2	11/2017	Ostroff et al.
9,008,777 B2	4/2015	Dianaty et al.	9,808,628 B2	11/2017	Sheldon et al.
9,014,818 B2	4/2015	Deterre et al.	9,808,631 B2	11/2017	Maile et al.
9,017,341 B2	4/2015	Bornzin et al.	9,808,632 B2	11/2017	Reinke et al.
9,020,611 B2	4/2015	Khairkhahan et al.	9,808,633 B2	11/2017	Bonner et al.
9,037,262 B2	5/2015	Regnier et al.	9,808,637 B2	11/2017	Sharma et al.
9,042,984 B2	5/2015	Demmer et al.	9,855,414 B2	1/2018	Marshall et al.
9,072,911 B2	7/2015	Hastings et al.	9,855,430 B2	1/2018	Ghosh et al.
9,072,913 B2	7/2015	Jacobson	9,855,435 B2	1/2018	Sahabi et al.
9,155,882 B2	10/2015	Grubac et al.	9,861,815 B2	1/2018	Tran et al.
9,168,372 B2	10/2015	Fain	10,080,887 B2	9/2018	Schmidt et al.
9,168,380 B1	10/2015	Greenhut et al.	10,080,888 B2	9/2018	Kelly et al.
9,168,383 B2	10/2015	Jacobson et al.	10,080,900 B2	9/2018	Ghosh et al.
9,180,285 B2	11/2015	Moore et al.	10,080,903 B2	9/2018	Willis et al.
9,192,774 B2	11/2015	Jacobson	10,086,206 B2	10/2018	Sambelashvili
9,205,225 B2	12/2015	Khairkhahan et al.	2002/0032470 A1	3/2002	Linberg
9,216,285 B1	12/2015	Boling et al.	2002/0035376 A1	3/2002	Bardy et al.
9,216,293 B2	12/2015	Berthiaume et al.	2002/0035377 A1	3/2002	Bardy et al.
9,216,298 B2	12/2015	Jacobson	2002/0035378 A1	3/2002	Bardy et al.
9,227,077 B2	1/2016	Jacobson	2002/0035380 A1	3/2002	Rissmann et al.
9,238,145 B2	1/2016	Wenzel et al.	2002/0035381 A1	3/2002	Bardy et al.
9,242,102 B2	1/2016	Khairkhahan et al.	2002/0042629 A1	4/2002	Bardy et al.
9,242,113 B2	1/2016	Smith et al.	2002/0042630 A1	4/2002	Bardy et al.
9,248,300 B2	2/2016	Rys et al.	2002/0042634 A1	4/2002	Bardy et al.
9,265,436 B2	2/2016	Min et al.	2002/0049475 A1	4/2002	Bardy et al.
9,265,962 B2	2/2016	Dianaty et al.	2002/0052636 A1	5/2002	Bardy et al.
9,272,155 B2	3/2016	Ostroff	2002/0068958 A1	6/2002	Bardy et al.
9,278,218 B2	3/2016	Karst et al.	2002/0072773 A1	6/2002	Bardy et al.
9,278,229 B1	3/2016	Reinke et al.	2002/0082665 A1	6/2002	Haller et al.
9,283,381 B2	3/2016	Grubac et al.	2002/0091414 A1	7/2002	Bardy et al.
9,283,382 B2	3/2016	Berthiaume et al.	2002/0095196 A1	7/2002	Linberg
9,289,612 B1	3/2016	Sambelashvili et al.	2002/0099423 A1	7/2002	Berg et al.
9,302,115 B2	4/2016	Molin et al.	2002/0103510 A1	8/2002	Bardy et al.
9,333,364 B2	5/2016	Echt et al.	2002/0107545 A1	8/2002	Rissmann et al.
9,358,387 B2	6/2016	Suwito et al.	2002/0107546 A1	8/2002	Ostroff et al.
9,358,400 B2	6/2016	Jacobson	2002/0107547 A1	8/2002	Erlinger et al.
9,364,675 B2	6/2016	Deterre et al.	2002/0107548 A1	8/2002	Bardy et al.
9,370,663 B2	6/2016	Moulder	2002/0107549 A1	8/2002	Bardy et al.
9,375,580 B2	6/2016	Bonner et al.	2002/0107559 A1	8/2002	Sanders et al.
9,375,581 B2	6/2016	Baru et al.	2002/0120299 A1	8/2002	Ostroff et al.
9,381,365 B2	7/2016	Kibler et al.	2002/0173830 A1	11/2002	Starkweather et al.
9,393,424 B2	7/2016	Demmer et al.	2002/0193846 A1	12/2002	Pool et al.
9,393,436 B2	7/2016	Doerr	2003/0009203 A1	1/2003	Lebel et al.
9,399,139 B2	7/2016	Demmer et al.	2003/0028082 A1	2/2003	Thompson
9,399,140 B2	7/2016	Cho et al.	2003/0040779 A1	2/2003	Engmark et al.
9,409,033 B2	8/2016	Jacobson	2003/0041866 A1	3/2003	Linberg et al.
9,427,594 B1	8/2016	Bornzin et al.	2003/0045805 A1	3/2003	Sheldon et al.
9,433,368 B2	9/2016	Stahmann et al.	2003/0088278 A1	5/2003	Bardy et al.
9,433,780 B2	9/2016	Régnier et al.	2003/0097153 A1	5/2003	Bardy et al.
9,457,193 B2	10/2016	Klimovitch et al.	2003/0105497 A1	6/2003	Zhu et al.
9,492,668 B2	11/2016	Sheldon et al.	2003/0114908 A1	6/2003	Flach
9,492,669 B2	11/2016	Demmer et al.	2003/0144701 A1	7/2003	Mehra et al.
9,492,674 B2	11/2016	Schmidt et al.	2003/0187460 A1	10/2003	Chin et al.
9,492,677 B2	11/2016	Greenhut et al.	2003/0187461 A1	10/2003	Chin
9,511,233 B2	12/2016	Sambelashvili	2004/0024435 A1	2/2004	Leckrone et al.
9,511,236 B2	12/2016	Varady et al.	2004/0068302 A1	4/2004	Rodgers et al.
9,511,237 B2	12/2016	Deterre et al.	2004/0087938 A1	5/2004	Leckrone et al.
9,522,276 B2	12/2016	Shen et al.	2004/0088035 A1	5/2004	Guenst et al.
9,522,280 B2	12/2016	Fishler et al.	2004/0102830 A1	5/2004	Williams
9,526,522 B2	12/2016	Wood et al.	2004/0127959 A1	7/2004	Amundson et al.
9,526,891 B2	12/2016	Eggen et al.	2004/0133242 A1	7/2004	Chapman et al.
9,526,909 B2	12/2016	Stahmann et al.	2004/0147969 A1	7/2004	Mann et al.
9,533,163 B2	1/2017	Klimovitch et al.	2004/0147973 A1	7/2004	Hauser
9,561,382 B2	2/2017	Persson et al.	2004/0167558 A1	8/2004	Igo et al.
9,566,012 B2	2/2017	Greenhut et al.	2004/0167587 A1	8/2004	Thompson
9,636,511 B2	5/2017	Carney et al.	2004/0172071 A1	9/2004	Bardy et al.
9,669,223 B2	6/2017	Auricchio et al.	2004/0172077 A1	9/2004	Chinchoy
			2004/0172104 A1	9/2004	Berg et al.
			2004/0176817 A1	9/2004	Wahlstrand et al.
			2004/0176818 A1	9/2004	Wahlstrand et al.
			2004/0176830 A1	9/2004	Fang

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2004/0186529	A1	9/2004	Bardy et al.	2008/0119911	A1	5/2008	Rosero
2004/0204673	A1	10/2004	Flaherty	2008/0130670	A1	6/2008	Kim et al.
2004/0210292	A1	10/2004	Bardy et al.	2008/0154139	A1	6/2008	Shuros et al.
2004/0210293	A1	10/2004	Bardy et al.	2008/0154322	A1	6/2008	Jackson et al.
2004/0210294	A1	10/2004	Bardy et al.	2008/0228234	A1	9/2008	Stancer
2004/0215308	A1	10/2004	Bardy et al.	2008/0234771	A1	9/2008	Chinchoy et al.
2004/0220624	A1	11/2004	Ritscher et al.	2008/0243217	A1	10/2008	Wildon
2004/0220626	A1	11/2004	Wagner	2008/0269814	A1	10/2008	Rosero
2004/0220639	A1	11/2004	Mulligan et al.	2008/0269825	A1	10/2008	Chinchoy et al.
2004/0230283	A1	11/2004	Prinzen et al.	2008/0275518	A1	11/2008	Ghanem et al.
2004/0249431	A1	12/2004	Ransbury et al.	2008/0275519	A1	11/2008	Ghanem et al.
2004/0260348	A1	12/2004	Bakken et al.	2008/0288039	A1	11/2008	Reddy
2004/0267303	A1	12/2004	Guenst	2008/0294208	A1	11/2008	Willis et al.
2005/0061320	A1	3/2005	Lee et al.	2008/0294210	A1	11/2008	Rosero
2005/0070962	A1	3/2005	Echt et al.	2008/0294229	A1	11/2008	Friedman et al.
2005/0102003	A1	5/2005	Grabek et al.	2008/0306359	A1	12/2008	Zdeblick et al.
2005/0149138	A1	7/2005	Min et al.	2009/0018599	A1	1/2009	Hastings et al.
2005/0165466	A1	7/2005	Morris et al.	2009/0024180	A1	1/2009	Kisker et al.
2005/0182465	A1	8/2005	Ness	2009/0036941	A1	2/2009	Corbucci
2005/0203410	A1	9/2005	Jenkins	2009/0048646	A1	2/2009	Katoozi et al.
2005/0283208	A1	12/2005	Von Arx et al.	2009/0062895	A1	3/2009	Stahmann et al.
2005/0288743	A1	12/2005	Ahn et al.	2009/0082827	A1	3/2009	Kveen et al.
2006/0042830	A1	3/2006	Maghribi et al.	2009/0082828	A1	3/2009	Ostroff
2006/0052829	A1	3/2006	Sun et al.	2009/0088813	A1	4/2009	Brockway et al.
2006/0052830	A1	3/2006	Spinelli et al.	2009/0131907	A1	5/2009	Chin et al.
2006/0064135	A1	3/2006	Brockway	2009/0135886	A1	5/2009	Robertson et al.
2006/0064149	A1	3/2006	Belacazar et al.	2009/0143835	A1	6/2009	Pastore et al.
2006/0085039	A1	4/2006	Hastings et al.	2009/0171408	A1	7/2009	Solem
2006/0085041	A1	4/2006	Hastings et al.	2009/0171414	A1	7/2009	Kelly et al.
2006/0085042	A1	4/2006	Hastings et al.	2009/0204163	A1	8/2009	Shuros et al.
2006/0095078	A1	5/2006	Tronnes	2009/0204170	A1	8/2009	Hastings et al.
2006/0106442	A1	5/2006	Richardson et al.	2009/0210024	A1	8/2009	M.
2006/0116746	A1	6/2006	Chin	2009/0216292	A1	8/2009	Pless et al.
2006/0135999	A1	6/2006	Bodner et al.	2009/0234407	A1	9/2009	Hastings et al.
2006/0136004	A1	6/2006	Cowan et al.	2009/0234411	A1	9/2009	Sambelashvili et al.
2006/0161061	A1	7/2006	Echt et al.	2009/0266573	A1	10/2009	Engmark et al.
2006/0200002	A1	9/2006	Guenst	2009/0275998	A1	11/2009	Bumes et al.
2006/0206151	A1	9/2006	Lu	2009/0275999	A1	11/2009	Bumes et al.
2006/0212079	A1	9/2006	Routh et al.	2009/0299447	A1	12/2009	Jensen et al.
2006/0241701	A1	10/2006	Markowitz et al.	2010/0013668	A1	1/2010	Kantervik
2006/0241705	A1	10/2006	Neumann et al.	2010/0016911	A1	1/2010	Willis et al.
2006/0247672	A1	11/2006	Vidlund et al.	2010/0023085	A1	1/2010	Wu et al.
2006/0259088	A1	11/2006	Pastore et al.	2010/0030061	A1	2/2010	Canfield et al.
2006/0265018	A1	11/2006	Smith et al.	2010/0030327	A1	2/2010	Chatel
2007/0004979	A1	1/2007	Wojciechowicz et al.	2010/0042108	A1	2/2010	Hibino
2007/0016098	A1	1/2007	Kim et al.	2010/0056871	A1	3/2010	Govari et al.
2007/0027508	A1	2/2007	Cowan	2010/0063375	A1	3/2010	Kassab et al.
2007/0078490	A1	4/2007	Cowan et al.	2010/0063562	A1	3/2010	Cowan et al.
2007/0088394	A1	4/2007	Jacobson	2010/0069983	A1	3/2010	Peacock, III et al.
2007/0088396	A1	4/2007	Jacobson	2010/0094367	A1	4/2010	Sen
2007/0088397	A1	4/2007	Jacobson	2010/0114209	A1	5/2010	Krause et al.
2007/0088398	A1	4/2007	Jacobson	2010/0114214	A1	5/2010	Morelli et al.
2007/0088405	A1	4/2007	Jacobson	2010/0125281	A1	5/2010	Jacobson et al.
2007/0135882	A1	6/2007	Drasler et al.	2010/0168761	A1	7/2010	Kassab et al.
2007/0135883	A1	6/2007	Drasler et al.	2010/0168819	A1	7/2010	Freeberg
2007/0150037	A1	6/2007	Hastings et al.	2010/0198288	A1	8/2010	Ostroff
2007/0150038	A1	6/2007	Hastings et al.	2010/0198304	A1	8/2010	Wang
2007/0156190	A1	7/2007	Cinbis	2010/0217367	A1	8/2010	Belson
2007/0219525	A1	9/2007	Gelfand et al.	2010/0228308	A1	9/2010	Cowan et al.
2007/0219590	A1	9/2007	Hastings et al.	2010/0234906	A1	9/2010	Koh
2007/0225545	A1	9/2007	Ferrari	2010/0234924	A1	9/2010	Willis
2007/0233206	A1	10/2007	Frikart et al.	2010/0241185	A1	9/2010	Mahapatra et al.
2007/0239244	A1	10/2007	Morgan et al.	2010/0249729	A1	9/2010	Morris et al.
2007/0255376	A1	11/2007	Michels et al.	2010/0286744	A1	11/2010	Echt et al.
2007/0276444	A1	11/2007	Gelbart et al.	2010/0298841	A1	11/2010	Prinzen et al.
2007/0293900	A1	12/2007	Sheldon et al.	2010/0312309	A1	12/2010	Harding
2007/0293904	A1	12/2007	Gelbart et al.	2011/0022113	A1	1/2011	Zdeblick et al.
2008/0004663	A1	1/2008	Jorgenson	2011/0071586	A1	3/2011	Jacobson
2008/0021505	A1	1/2008	Hastings et al.	2011/0077708	A1	3/2011	Ostroff
2008/0021519	A1	1/2008	De Geest et al.	2011/0112600	A1	5/2011	Cowan et al.
2008/0021532	A1	1/2008	Kveen et al.	2011/0118588	A1	5/2011	Komblau et al.
2008/0065183	A1	3/2008	Whitehurst et al.	2011/0118810	A1	5/2011	Cowan et al.
2008/0065185	A1	3/2008	Worley	2011/0137187	A1	6/2011	Yang et al.
2008/0071318	A1	3/2008	Brooke et al.	2011/0144720	A1	6/2011	Cowan et al.
2008/0109054	A1	5/2008	Hastings et al.	2011/0152970	A1	6/2011	Jollota et al.
				2011/0160558	A1	6/2011	Rassatt et al.
				2011/0160565	A1	6/2011	Stubbs et al.
				2011/0160801	A1	6/2011	Markowitz et al.
				2011/0160806	A1	6/2011	Lyden et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2011/0166620 A1	7/2011	Cowan et al.	2013/0103047 A1	4/2013	Steingisser et al.
2011/0166621 A1	7/2011	Cowan et al.	2013/0103109 A1	4/2013	Jacobson
2011/0184491 A1	7/2011	Kivi	2013/0110008 A1	5/2013	Bourget et al.
2011/0190835 A1	8/2011	Brockway et al.	2013/0110127 A1	5/2013	Bornzin et al.
2011/0208260 A1	8/2011	Jacobson	2013/0110192 A1	5/2013	Tran et al.
2011/0218587 A1	9/2011	Jacobson	2013/0110219 A1	5/2013	Bornzin et al.
2011/0230734 A1	9/2011	Fain et al.	2013/0116529 A1	5/2013	Min et al.
2011/0237967 A1	9/2011	Moore et al.	2013/0116738 A1	5/2013	Samade et al.
2011/0245890 A1	10/2011	Brisben et al.	2013/0116740 A1	5/2013	Bornzin et al.
2011/0251660 A1	10/2011	Griswold	2013/0116741 A1	5/2013	Bornzin et al.
2011/0251662 A1	10/2011	Griswold et al.	2013/0123872 A1	5/2013	Bornzin et al.
2011/0270099 A1	11/2011	Ruben et al.	2013/0123875 A1	5/2013	Varady et al.
2011/0270339 A1	11/2011	Murray, III et al.	2013/0131591 A1	5/2013	Berthiaume et al.
2011/0270340 A1	11/2011	Pellegrini et al.	2013/0131693 A1	5/2013	Berthiaume et al.
2011/0270341 A1	11/2011	Ruben et al.	2013/0138006 A1	5/2013	Bornzin et al.
2011/0276102 A1	11/2011	Cohen	2013/0150695 A1	6/2013	Biela et al.
2011/0282423 A1	11/2011	Jacobson	2013/0150911 A1	6/2013	Perschbacher et al.
2012/0004527 A1	1/2012	Thompson et al.	2013/0150912 A1	6/2013	Perschbacher et al.
2012/0029323 A1	2/2012	Zhao	2013/0184776 A1	7/2013	Shuros et al.
2012/0041508 A1	2/2012	Rouso et al.	2013/0192611 A1	8/2013	Taepke, II et al.
2012/0059433 A1	3/2012	Cowan et al.	2013/0196703 A1	8/2013	Masoud et al.
2012/0059436 A1	3/2012	Fontaine et al.	2013/0197609 A1	8/2013	Moore et al.
2012/0065500 A1	3/2012	Rogers et al.	2013/0231710 A1	9/2013	Jacobson
2012/0078322 A1	3/2012	Dal Molin et al.	2013/0238072 A1	9/2013	Deterre et al.
2012/0089198 A1	4/2012	Ostroff	2013/0238073 A1	9/2013	Makdissi et al.
2012/0093245 A1	4/2012	Makdissi et al.	2013/0253309 A1	9/2013	Allan et al.
2012/0095521 A1	4/2012	Hintz	2013/0253342 A1	9/2013	Griswold et al.
2012/0095539 A1	4/2012	Khairkhahan et al.	2013/0253343 A1	9/2013	Waldhauser et al.
2012/0101540 A1	4/2012	O'Brien et al.	2013/0253344 A1	9/2013	Griswold et al.
2012/0101546 A1	4/2012	Stadler et al.	2013/0253345 A1	9/2013	Griswold et al.
2012/0101553 A1	4/2012	Reddy	2013/0253346 A1	9/2013	Griswold et al.
2012/0109148 A1	5/2012	Bonner et al.	2013/0253347 A1	9/2013	Griswold et al.
2012/0109149 A1	5/2012	Bonner et al.	2013/0261497 A1	10/2013	Pertijs et al.
2012/0109236 A1	5/2012	Jacobson et al.	2013/0265144 A1	10/2013	Banna et al.
2012/0109259 A1	5/2012	Bond et al.	2013/0268042 A1	10/2013	Hastings et al.
2012/0116489 A1	5/2012	Khairkhahan et al.	2013/0274828 A1	10/2013	Willis
2012/0150251 A1	6/2012	Giftakis et al.	2013/0274847 A1	10/2013	Ostroff
2012/0158111 A1	6/2012	Khairkhahan et al.	2013/0282070 A1	10/2013	Cowan et al.
2012/0165827 A1	6/2012	Khairkhahan et al.	2013/0282073 A1	10/2013	Cowan et al.
2012/0172690 A1	7/2012	Anderson et al.	2013/0296727 A1	11/2013	Sullivan et al.
2012/0172891 A1	7/2012	Lee	2013/0303872 A1	11/2013	Taff et al.
2012/0172892 A1	7/2012	Grubac et al.	2013/0324825 A1	12/2013	Ostroff et al.
2012/0172942 A1	7/2012	Berg	2013/0325081 A1	12/2013	Karst et al.
2012/0197350 A1	8/2012	Roberts et al.	2013/0345770 A1	12/2013	Dianaty et al.
2012/0197373 A1	8/2012	Khairkhahan et al.	2014/0012344 A1	1/2014	Hastings et al.
2012/0215285 A1	8/2012	Tahmasian et al.	2014/0018876 A1	1/2014	Ostroff
2012/0232565 A1	9/2012	Kveen et al.	2014/0018877 A1	1/2014	Demmer et al.
2012/0245665 A1	9/2012	Friedman et al.	2014/0031836 A1	1/2014	Ollivier
2012/0277600 A1	11/2012	Greenhut	2014/0039570 A1	2/2014	Carroll et al.
2012/0277606 A1	11/2012	Ellingson et al.	2014/0039591 A1	2/2014	Drasler et al.
2012/0283795 A1	11/2012	Stancer et al.	2014/0043146 A1	2/2014	Makdissi et al.
2012/0283807 A1	11/2012	Deterre et al.	2014/0046395 A1	2/2014	Regnier et al.
2012/0289776 A1	11/2012	Keast et al.	2014/0046420 A1	2/2014	Moore et al.
2012/0289815 A1	11/2012	Keast et al.	2014/0058240 A1	2/2014	Mothilal et al.
2012/0290021 A1	11/2012	Saurkar et al.	2014/0058494 A1	2/2014	Ostroff et al.
2012/0290025 A1	11/2012	Keimel	2014/0074114 A1	3/2014	Khairkhahan et al.
2012/0296381 A1	11/2012	Matos	2014/0074186 A1	3/2014	Faltys et al.
2012/0303082 A1	11/2012	Dong et al.	2014/0094891 A1	4/2014	Pare et al.
2012/0316613 A1	12/2012	Keefe et al.	2014/0100624 A1	4/2014	Ellingson
2013/0012151 A1	1/2013	Hankins	2014/0100627 A1	4/2014	Min
2013/0023975 A1	1/2013	Locsin	2014/0107723 A1	4/2014	Hou et al.
2013/0035748 A1	2/2013	Bonner et al.	2014/0121719 A1	5/2014	Bonner et al.
2013/0041422 A1	2/2013	Jacobson	2014/0121720 A1	5/2014	Bonner et al.
2013/0053908 A1	2/2013	Smith et al.	2014/0121722 A1	5/2014	Sheldon et al.
2013/0053915 A1	2/2013	Holmstrom et al.	2014/0128935 A1	5/2014	Kumar et al.
2013/0053921 A1	2/2013	Bonner et al.	2014/0135865 A1	5/2014	Hastings et al.
2013/0060298 A1	3/2013	Splett et al.	2014/0142648 A1	5/2014	Smith et al.
2013/0066169 A1	3/2013	Rys et al.	2014/0148675 A1	5/2014	Nordstrom et al.
2013/0072770 A1	3/2013	Rao et al.	2014/0148815 A1	5/2014	Wenzel et al.
2013/0079798 A1	3/2013	Tran et al.	2014/0155950 A1	6/2014	Hastings et al.
2013/0079861 A1	3/2013	Reinert et al.	2014/0169162 A1	6/2014	Romano et al.
2013/0085350 A1	4/2013	Schugt et al.	2014/0172060 A1	6/2014	Bornzin et al.
2013/0085403 A1	4/2013	Gunderson et al.	2014/0180306 A1	6/2014	Grubac et al.
2013/0085550 A1	4/2013	Polefko et al.	2014/0180366 A1	6/2014	Edlund
2013/0096649 A1	4/2013	Martin et al.	2014/0207149 A1	7/2014	Hastings et al.
			2014/0207210 A1	7/2014	Willis et al.
			2014/0214104 A1	7/2014	Greenhut et al.
			2014/0222015 A1	8/2014	Keast et al.
			2014/0222098 A1	8/2014	Baru et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

2014/0222109 A1 8/2014 Moulder  
 2014/0228913 A1 8/2014 Molin et al.  
 2014/0236172 A1 8/2014 Hastings et al.  
 2014/0243848 A1 8/2014 Auricchio et al.  
 2014/0255298 A1 9/2014 Cole et al.  
 2014/0257324 A1 9/2014 Fain  
 2014/0257422 A1 9/2014 Herken  
 2014/0257444 A1 9/2014 Cole et al.  
 2014/0276929 A1 9/2014 Foster et al.  
 2014/0303704 A1 10/2014 Suwito et al.  
 2014/0309706 A1 10/2014 Jacobson  
 2014/0343348 A1 11/2014 Kaplan et al.  
 2014/0371818 A1 12/2014 Bond et al.  
 2014/0379041 A1 12/2014 Foster  
 2015/0025612 A1 1/2015 Haasl et al.  
 2015/0039041 A1 2/2015 Smith et al.  
 2015/0045868 A1 2/2015 Bonner et al.  
 2015/0051609 A1 2/2015 Schmidt et al.  
 2015/0051610 A1 2/2015 Schmidt et al.  
 2015/0051611 A1 2/2015 Schmidt et al.  
 2015/0051612 A1 2/2015 Schmidt et al.  
 2015/0051613 A1 2/2015 Schmidt et al.  
 2015/0051614 A1 2/2015 Schmidt et al.  
 2015/0051615 A1 2/2015 Schmidt et al.  
 2015/0051616 A1 2/2015 Haasl et al.  
 2015/0051682 A1 2/2015 Schmidt et al.  
 2015/0057520 A1 2/2015 Foster et al.  
 2015/0057558 A1 2/2015 Stahmann et al.  
 2015/0057721 A1 2/2015 Stahmann et al.  
 2015/0088155 A1 3/2015 Stahmann et al.  
 2015/0105836 A1 4/2015 Bonner et al.  
 2015/0126854 A1 5/2015 Keast et al.  
 2015/0157861 A1 6/2015 Aghassian  
 2015/0157866 A1 6/2015 Demmer et al.  
 2015/0173655 A1 6/2015 Demmer et al.  
 2015/0190638 A1 7/2015 Smith et al.  
 2015/0196756 A1 7/2015 Stahmann et al.  
 2015/0196757 A1 7/2015 Stahmann et al.  
 2015/0196758 A1 7/2015 Stahmann et al.  
 2015/0196769 A1 7/2015 Stahmann et al.  
 2015/0217119 A1 8/2015 Nikolski et al.  
 2015/0221898 A1 8/2015 Chi et al.  
 2015/0224315 A1 8/2015 Stahmann  
 2015/0224320 A1 8/2015 Stahmann  
 2015/0230699 A1 8/2015 Berul et al.  
 2015/0238769 A1 8/2015 Demmer et al.  
 2015/0258345 A1 9/2015 Smith et al.  
 2015/0290468 A1 10/2015 Zhang  
 2015/0297905 A1 10/2015 Greenhut et al.  
 2015/0297907 A1 10/2015 Zhang  
 2015/0305637 A1 10/2015 Greenhut et al.  
 2015/0305638 A1 10/2015 Zhang  
 2015/0305639 A1 10/2015 Greenhut et al.  
 2015/0305640 A1 10/2015 Reinke et al.  
 2015/0305641 A1 10/2015 Stadler et al.  
 2015/0305642 A1 10/2015 Reinke et al.  
 2015/0306374 A1 10/2015 Seifert et al.  
 2015/0306375 A1 10/2015 Marshall et al.  
 2015/0306401 A1 10/2015 Demmer et al.  
 2015/0306406 A1 10/2015 Crutchfield et al.  
 2015/0306407 A1 10/2015 Crutchfield et al.  
 2015/0306408 A1 10/2015 Greenhut et al.  
 2015/0321011 A1 11/2015 Carney et al.  
 2015/0321016 A1 11/2015 O'Brien et al.  
 2015/0328459 A1 11/2015 Chin et al.  
 2015/0335884 A1 11/2015 Khairkahan et al.  
 2016/0015322 A1 1/2016 Anderson et al.  
 2016/0023000 A1 1/2016 Cho et al.  
 2016/0030757 A1 2/2016 Jacobson  
 2016/0033177 A1 2/2016 Barot et al.  
 2016/0121127 A1 5/2016 Klimovitch et al.  
 2016/0121128 A1 5/2016 Fishler et al.  
 2016/0121129 A1 5/2016 Persson et al.  
 2016/0213919 A1 7/2016 Suwito et al.  
 2016/0213937 A1 7/2016 Reinke et al.

2016/0213939 A1 7/2016 Carney et al.  
 2016/0228026 A1 8/2016 Jackson  
 2016/0317825 A1 11/2016 Jacobson  
 2016/0367823 A1 12/2016 Cowan et al.  
 2017/0014629 A1 1/2017 Ghosh et al.  
 2017/0035315 A1 2/2017 Jackson  
 2017/0043173 A1 2/2017 Sharma et al.  
 2017/0043174 A1 2/2017 Greenhut et al.  
 2017/0189681 A1 7/2017 Anderson  
 2017/0281261 A1 10/2017 Shuros et al.  
 2017/0281952 A1 10/2017 Shuros et al.  
 2017/0281953 A1 10/2017 Min et al.  
 2017/0281955 A1 10/2017 Maile et al.  
 2017/0312531 A1 11/2017 Sawchuk  
 2018/0256902 A1 9/2018 Toy et al.  
 2018/0256909 A1 9/2018 Smith et al.  
 2018/0264262 A1 9/2018 Haasl et al.  
 2018/0264270 A1 9/2018 Koop et al.  
 2018/0264272 A1 9/2018 Haasl et al.  
 2018/0264273 A1 9/2018 Haasl et al.  
 2018/0264274 A1 9/2018 Haasl et al.

## FOREIGN PATENT DOCUMENTS

AU 2014203793 A1 7/2014  
 CA 1003904 A1 1/1977  
 CN 202933393 U 5/2013  
 EP 0362611 A1 4/1990  
 EP 503823 A2 9/1992  
 EP 1702648 A2 9/2006  
 EP 1904166 B1 6/2011  
 EP 2471452 A1 7/2012  
 EP 2433675 B1 1/2013  
 EP 2441491 B1 1/2013  
 EP 2452721 B1 11/2013  
 EP 2662113 A3 11/2013  
 EP 1948296 B1 1/2014  
 EP 2760541 B1 5/2016  
 EP 2833966 B1 5/2016  
 JP 2000051373 A 2/2000  
 JP 2002502640 A 1/2002  
 JP 2004512105 A 4/2004  
 JP 2005508208 A 3/2005  
 JP 2005245215 A 9/2005  
 JP 2008540040 A 11/2008  
 JP 5199867 B2 2/2013  
 WO 9500202 A1 1/1995  
 WO 9636134 A1 11/1996  
 WO 9724981 A2 7/1997  
 WO 9826840 A1 6/1998  
 WO 9939767 A1 8/1999  
 WO 0234330 A2 5/2002  
 WO 02098282 A2 12/2002  
 WO 2005000206 A3 1/2005  
 WO 2005042089 A1 5/2005  
 WO 2006065394 A1 6/2006  
 WO 2006086435 A3 8/2006  
 WO 2006113659 A1 10/2006  
 WO 2006124833 A3 11/2006  
 WO 2007073435 A1 6/2007  
 WO 2007075974 A2 7/2007  
 WO 2009006531 A1 1/2009  
 WO 2012054102 A1 4/2012  
 WO 2013080038 A2 6/2013  
 WO 2013098644 A3 7/2013  
 WO 2013184787 A1 12/2013  
 WO 2014120769 A1 8/2014  
 WO 2015179177 A1 11/2015

## OTHER PUBLICATIONS

"Instructions for Use System 1, Leadless Cardiac Pacemaker (LCP) and Delivery Catheter," Nanostim Leadless Pacemakers, pp. 1-28, 2013.  
 Hachisuka et al., "Development and Performance Analysis of an Intra-Body Communication Device," The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003.

(56)

**References Cited**

OTHER PUBLICATIONS

Seyedi et al., "A Survey on Intrabody Communications for Body Area Network Application," IEEE Transactions on Biomedical Engineering, vol. 60(8): 2067-2079, 2013.

Spickler et al., "Totally Self-Contained Intracardiac Pacemaker," Journal of Electrocardiology, vol. 3(384): 324-331, 1970.

Wegmüller, "Intra-Body Communication for Biomedical Sensor Networks," Diss. ETH, No. 17323, 1-173, 2007.

Invitation to Pay Additional Fees and, Where Applicable, Protest Fee for Application No. PCT/US2017/060211, 13 pages, dated Mar. 9, 2018.




Figure 1




Figure 2




Figure 3




Figure 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12

1

**SYSTEMS, DEVICES, AND METHODS FOR  
SETTING CARDIAC PACING PULSE  
PARAMETERS FOR A CARDIAC PACING  
DEVICE**

CROSS REFERENCE TO RELATED  
APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/419,731 filed on Nov. 9, 2016, the disclosure of which is incorporated herein by reference.

TECHNICAL FIELD

The present disclosure generally relates to cardiac pacing devices, and more particularly to systems, devices, and methods for setting pacing pulse parameters for such cardiac pacing devices.

BACKGROUND

Pacing instruments can be used to treat patients suffering from various heart conditions that result in a reduced ability of the heart to deliver sufficient amounts of blood to a patient's body. These heart conditions may lead to rapid, irregular, and/or inefficient heart contractions. To help alleviate some of these conditions, various devices (e.g., pacemakers, defibrillators, etc.) can be implanted in a patient's body. Such devices may monitor and provide electrical stimulation to the heart to help the heart operate in a more normal, efficient and/or safe manner. What would be desirable are improved systems, devices, and methods for setting pacing pulse parameters for such devices.

SUMMARY

The present disclosure generally relates to cardiac pacing devices, and more particularly to systems, devices, and methods for setting pacing pulse parameters for such cardiac pacing devices.

In an illustrative embodiment, the cardiac pacing device may include a leadless cardiac pacemaker (LCP). The leadless cardiac pacemaker may be configured to be implanted in or on a patient's heart and may deliver pacing pulses to the patient's heart. While a leadless cardiac pacemaker is used as an example in this disclosure, it is contemplated that the concepts disclosed herein may be applied to any suitable cardiac pacing device that is configured to delivery cardiac pacing pulses to a patient's heart.

An illustrative leadless cardiac pacemaker may comprise a power supply for providing a power supply voltage, a pair of electrodes for delivering pacing pulses to the heart of the patient, and a controller operably connected to the pair of electrodes and the power supply. The controller may identify a capture threshold and deliver, via the pair of electrodes, a plurality of pacing pulses each having a pace amplitude and a pacing pulse width. The controller may identify a capture threshold by setting the pace amplitude to the power supply voltage and then deliver, via the pair of electrodes, a plurality of pacing pulses having the pace amplitude with different pulse widths to identify the capture pulse width that corresponds to the capture threshold of the heart. Once the capture pulse width has been identified, the controller may deliver via the pair of electrodes a plurality of pacing pulses having the pace amplitude and a pacing pulse width that is greater than the capture pulse width by a pulse width margin.

2

By having the pace amplitude set to the power supply voltage (e.g. battery voltage), little or no power supply energy (e.g. battery energy) is wasted in converting the power supply voltage to the pace amplitude. In some cases, this can significantly increase the useful life expectancy of the leadless cardiac pacemaker.

Additionally, or alternatively to the first illustrative embodiment, the power supply may comprise a battery, and the power supply voltage may comprise a battery voltage provided by the battery.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the battery voltage, and thus the pace amplitude, may decay over time.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the controller may be configured to identify the capture threshold from time to time.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the controller may store data representing one or more strength-duration curves, and the controller may be configured to identify a capture threshold strength-duration curve based at least in part on the pace amplitude and the capture pulse width, and the controller may be further configured to identify the pulse width margin by referencing a different one of the strength-duration curves and the pace amplitude.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, wherein if the power supply voltage changes, and thus the pace amplitude changes, the controller may be configured to automatically adjust the pacing pulse width based at least in part on the different one of the strength-duration curves and the changed pace amplitude, without having to update the capture threshold by delivering via the pair of electrodes a plurality of pacing pulses having the changed pace amplitude and different pulse widths.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the controller may be configured to receive the data representing the one or more strength-duration curves from a remote device.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the controller may be further configured to receive a user selectable power efficiency value, and wherein the pulse width margin may be based, at least in part, on the user selectable power efficiency value.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the user selectable power efficiency value may be received from a remote device.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the remote device may comprise a user interface including a display, wherein a user may use the user interface to select the user selectable power efficiency value.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the user interface may display a slider that allows the user to select the user selectable power efficiency value from a range of allowable user selectable power efficiency values.

Additionally, or alternatively, in any of the above embodiments with respect to the first illustrative embodiment, the user interface may display a dynamic indicator of an expected life time of the leadless cardiac pacemaker based, at least in part, on the user selectable power efficiency value.

In second illustrative embodiment, a leadless cardiac pacemaker system for delivering pacing pulses to a heart of a patient may comprise a remote device and a leadless cardiac pacemaker that is in communication with the remote device. The remote device may have a user interface with a display for receiving a selection of a user selectable power efficiency value. The leadless cardiac pacemaker may comprise a power supply for providing a power supply voltage, a pair of electrodes for delivering pacing pulses to the heart of the patient, and a controller operably connected to the pair of electrodes and the power supply. The controller identifies a pulse width and pulse amplitude combination that corresponds to a capture threshold. The controller may also receive the user selectable power efficiency value from the remote device, and may apply a capture margin to one or more of the pulse width and pulse amplitude that correspond to the capture threshold, resulting in a pacing pulse width and a pacing pulse amplitude. The capture margin may be based at least in part on the user selectable power efficiency value. The controller may then deliver pacing pulses to the heart using the pacing pulse width and the pacing pulse amplitude.

Additionally, or alternatively, the second illustrative embodiment may further comprise the controller being configured to store data representing one or more strength-duration curves, and wherein the controller may be configured to identify the capture margin by indexing the user selectable power efficiency value into the data representing one or more strength-duration curves.

Additionally, or alternatively, to any of the above embodiments with respect to the second illustrative embodiment, wherein the remote device displays on the display a slider that allows the user to select the user selectable power efficiency value from a range of allowable user selectable power efficiency values, and a dynamic indicator of an expected life time of the leadless cardiac pacemaker based, at least in part, on the user selectable power efficiency value.

In a third illustrative embodiment, a leadless cardiac pacemaker (LCP) for delivering pacing pulses to a heart of a patient may comprise a pair of electrodes for delivering pacing pulses to the heart of the patient and a controller operably connected to the pair of electrodes. The controller may identify a capture threshold by delivering via the pair of electrodes a plurality of pacing pulses while varying a first pacing pulse parameter value while leaving a second pacing pulse parameter value fixed in order to identify a capture value for the first pacing pulse parameter. Further, the controller may deliver via the pair of electrodes a plurality of pacing pulses that each have the first pacing pulse parameter value at the capture value and the second pacing pulse parameter value at a capture margin above the fixed second pacing pulse parameter value.

Additionally, or alternatively, the third illustrative embodiment may further comprise wherein the first pacing pulse parameter is pulse width and the second pacing pulse parameter is pulse amplitude.

Additionally, or alternatively, to any of the above embodiments with respect to the third illustrative embodiment, the leadless cardiac pacemaker may further comprise a battery that provides a battery voltage, and wherein the fixed second pacing pulse parameter value may be a predetermined fraction of the battery voltage.

Additionally, or alternatively, to any of the above embodiments with respect to the third illustrative embodiment, the second pacing pulse parameter value at the capture margin above the fixed second pacing pulse parameter value may correspond to the battery voltage.

Additionally, or alternatively, to any of the above embodiments with respect to the third illustrative embodiment, the first pacing pulse parameter may be pulse amplitude and the second pacing pulse parameter may be pulse width.

Additionally, or alternatively, to any of the above embodiments with respect to the third illustrative embodiment, the controller may store data representing one or more strength-duration curves, and the controller may be configured to identify the capture margin based at least in part on one or more of the strength-duration curves.

In a fourth illustrative embodiment, a leadless cardiac pacemaker (LCP) for delivering pacing pulses to a heart of a patient may comprise a pair of electrodes for delivering pacing pulses to the heart of the patient and a controller operably connected to the pair of electrodes. The controller identifies a pulse width and pulse amplitude combination that corresponds to a capture threshold. The controller may also receive a user selectable power efficiency value from a remote device. The controller may apply a capture margin to one or more of the pulse width and pulse amplitude that correspond to the capture threshold, resulting in a pacing pulse width and a pacing pulse amplitude. The capture margin may be based, at least in part, on the user selectable power efficiency value. The controller may then deliver pacing pulses using the pacing pulse width and the pacing pulse amplitude.

Additionally, or alternatively, the fourth illustrative embodiment may further comprise the controller being configured to store data representing one or more strength-duration curves, and wherein the controller may be configured to identify the capture margin by indexing the user selectable power efficiency value into the data representing one or more strength-duration curves.

Additionally, or alternatively, to any of the above embodiments with respect to the fourth illustrative embodiment, the controller may be configured to receive the data representing one or more strength-duration curves from the remote device.

Additionally, or alternatively, to any of the above embodiments with respect to the fourth illustrative embodiment, the remote device may comprise a user interface including a display, wherein a user may use the user interface to select the user selectable power efficiency value.

Additionally, or alternatively, to any of the above embodiments with respect to the fourth illustrative embodiment, the remote device may display a slider on the display that allows the user select the user selectable power efficiency value from a range of allowable user selectable power efficiency values.

Additionally, or alternatively, to any of the above embodiments with respect to the fourth illustrative embodiment, the remote device may display a dynamic indicator of an expected life time of the leadless cardiac pacemaker based, at least in part, on the user selectable power efficiency value.

Additionally, or alternatively, to any of the above embodiments with respect to the fourth illustrative embodiment, the leadless cardiac pacemaker may further comprise a battery for providing a battery voltage, and wherein the pacing pulse amplitude is set to the battery voltage.

The above summary is not intended to describe each embodiment or every implementation of the present disclosure. Advantages and attainments, together with a more complete understanding of the disclosure, will become apparent and appreciated by referring to the following description and claims taken in conjunction with the accompanying drawings.

## BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of the following description of various illustrative embodiments in connection with the accompanying drawings, in which:

FIG. 1 is a schematic block diagram of an illustrative leadless cardiac pacemaker (LCP);

FIG. 2 is a schematic block diagram of another illustrative medical device;

FIG. 3 is a schematic diagram of an exemplary medical system that includes multiple LCPs and/or other devices in communication with one another;

FIG. 4 is a schematic diagram of a system including an LCP and another medical device, in accordance with another embodiment of the present disclosure;

FIG. 5 depicts a schematic flow diagram of an illustrative method for providing pacing stimulation pulses from an LCP;

FIG. 6 depicts a schematic flow diagram of an illustrative method for identifying a capture threshold with an LCP;

FIG. 7 depicts a graph of an illustrative strength-duration curve;

FIG. 8 depicts a graph of a plurality of illustrative strength-duration curves;

FIG. 9 depicts a schematic diagram of an illustrative user interface of a remote device used in conjunction with an LCP;

FIG. 10 depicts a schematic flow diagram of an illustrative method for setting parameters of a pacing stimulation pulse provided by an LCP;

FIG. 11 depicts a schematic flow diagram of another illustrative method for setting parameters of a pacing stimulation pulse provided by an LCP; and

FIG. 12 depicts a schematic flow diagram of an illustrative method for adjusting, over time, parameters of a pacing stimulation pulse provided by an LCP.

While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of embodiment in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular illustrative embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.

## DESCRIPTION

The following description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The description and the drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure.

The present disclosure generally relates to cardiac pacing devices, and more particularly to systems, devices, and methods for setting pacing pulse parameters for such cardiac pacing devices. In an illustrative embodiment, the cardiac pacing device may include a leadless cardiac pacemaker (LCP). The leadless cardiac pacemaker may be configured to be implanted in or on a patient's heart and may deliver pacing pulses to the patient's heart. While a leadless cardiac pacemaker is used as an example in this disclosure, it is contemplated that the concepts disclosed herein may be applied to any suitable cardiac pacing device that is configured to delivery cardiac pacing pulses to a patient's heart.

FIG. 1 is a schematic block diagram of an illustrative leadless cardiac pacemaker (LCP). The illustrative LCP may be implanted on the heart or within a chamber of the heart and may operate to sense physiological signals and parameters and deliver one or more types of electrical stimulation therapy to the heart of the patient. Example electrical stimulation therapy may include bradycardia pacing, rate responsive pacing therapy, cardiac resynchronization therapy (CRT), anti-tachycardia pacing (ATP) therapy and/or the like. The disclosed concepts may be implemented in other IMDs and/or other devices including, but not limited to, pacemakers with leads, defibrillators, and/or other implantable or non-implantable devices.

As can be seen in FIG. 1, LCP 100 may be a compact device with all components housed within LCP 100 or directly on housing 120. In some instances, LCP 100 may include communication module 102, pulse generator module 104, electrical sensing module 106 (e.g., including one or more electrical sensors), mechanical sensing module 108 (e.g., including one or more mechanical sensors), processing module 110 (e.g., a controller including memory and one or more processors), energy storage module 112, and electrodes 114, 114'. Via circuitry, the electrodes 114, 114' may be part of and/or may be in communication with (e.g., operatively coupled to) the communication module 102, the pulse generator module 104, electrical sensing module 106, the mechanical sensing module 108, the processing module 110, and/or the energy storage module 112.

As depicted in FIG. 1, LCP 100 may include electrodes 114, which can be secured relative to housing 120 and electrically exposed to tissue and/or blood surrounding LCP 100. Electrodes 114 may generally conduct electrical signals to and/or from LCP 100 and the surrounding tissue and/or blood. Such electrical signals may include communication signals, electrical stimulation pulses, and intrinsic cardiac electrical signals, to name a few. Intrinsic cardiac electrical signals may include electrical signals generated by the heart and may be represented by an electrocardiogram (ECG). The electrodes may be considered a sensor capable of sensing each of a plurality of heart beats.

Electrodes 114 may include one or more biocompatible conductive materials such as various metals or alloys that are known to be safe for implantation within a human body. In some instances, electrodes 114 may be generally disposed on either end of LCP 100 and may be in electrical communication with one or more of modules 102, 104, 106, 108, and 110. In embodiments where electrodes 114 (e.g., two or more electrodes 114) are secured directly to housing 120, an insulative material may electrically isolate the electrodes 114 from adjacent electrodes, housing 120, and/or other parts of LCP 100. In some instances, some or all of electrodes 114 may be spaced from housing 120 and connected to housing 120 and/or other components of LCP 100 through connecting wires. In such instances, the electrodes 114 may be placed on a tail (not shown) that extends out away from the housing 120.

As shown in FIG. 1, in some embodiments, LCP 100 may include electrodes 114'. Electrodes 114' may be in addition to electrodes 114, or may replace one or more of electrodes 114. Electrodes 114' may be similar to electrodes 114 except that electrodes 114' are disposed on the sides of LCP 100. In some cases, electrodes 114' may increase the number of electrodes by which LCP 100 may deliver communication signals and/or electrical stimulation pulses, and/or may sense intrinsic cardiac electrical signals, communication signals, and/or electrical stimulation pulses.

Electrodes **114** and/or **114'** may assume any of a variety of sizes and/or shapes, and may be spaced at any of a variety of spacings. For example, electrodes **114** may have an outer diameter of two to twenty millimeters (mm). In other embodiments, electrodes **114** and/or **114'** may have a diameter of two, three, five, seven millimeters (mm), or any other suitable diameter, dimension and/or shape. Example lengths for electrodes **114** and/or **114'** may include, for example, one, three, five, ten millimeters (mm), or any other suitable length. As used herein, the length is a dimension of electrodes **114** and/or **114'** that extends away from the outer surface of the housing **120**. In some instances, at least some of electrodes **114** and/or **114'** may be spaced from one another by a distance of twenty, thirty, forty, fifty millimeters (mm), or any other suitable spacing. The electrodes **114** and/or **114'** of a single device may have different sizes with respect to each other, and the spacing and/or lengths of the electrodes on the device may or may not be uniform.

In the embodiment shown, communication module **102** may be electrically coupled to electrodes **114** and/or **114'** and may be configured to deliver communication pulses to tissues of the patient for communicating with other devices such as sensors, programmers, other medical devices, and/or the like. Communication signals, as used herein, may be any modulated signal that conveys information to another device, either by itself or in conjunction with one or more other modulated signals. In some embodiments, communication signals may be limited to sub-threshold signals that do not result in capture of the heart yet still convey information. The communication signals may be delivered to another device that is located either external or internal to the patient's body. In some instances, the communication may take the form of distinct communication pulses separated by various amounts of time. In some of these cases, the timing between successive pulses may convey information. Communication module **102** may additionally be configured to sense for communication signals delivered by other devices, which may be located external or internal to the patient's body.

Communication module **102** may communicate to help accomplish one or more desired functions. Some example functions include delivering sensed data, using communicated data for determining occurrences of events such as arrhythmias, coordinating delivery of electrical stimulation therapy, and/or other functions. In some cases, LCP **100** may use communication signals to communicate raw information, processed information, messages and/or commands, and/or other data. Raw information may include information such as sensed electrical signals (e.g. a sensed ECG), signals gathered from coupled sensors, and the like. In some embodiments, the processed information may include signals that have been filtered using one or more signal processing techniques. Processed information may also include parameters and/or events that are determined by the LCP **100** and/or another device, such as a determined heart rate, timing of determined heartbeats, timing of other determined events, determinations of threshold crossings, expirations of monitored time periods, accelerometer signals, activity level parameters, blood-oxygen parameters, blood pressure parameters, heart sound parameters, and the like. Messages and/or commands may include instructions or the like directing another device to take action, notifications of imminent actions of the sending device, requests for reading from the receiving device, requests for writing data to the receiving device, information messages, and/or other messages commands.

In at least some embodiments, communication module **102** (or LCP **100**) may further include switching circuitry to selectively connect one or more of electrodes **114** and/or **114'** to communication module **102** in order to select which electrodes **114** and/or **114'** that communication module **102** delivers communication pulses. It is contemplated that communication module **102** may be communicating with other devices via conducted signals, radio frequency (RF) signals, optical signals, acoustic signals, inductive coupling, and/or any other suitable communication methodology.

Where communication module **102** generates electrical communication signals, communication module **102** may include one or more capacitor elements and/or other charge storage devices to aid in generating and delivering communication signals. In the embodiment shown, communication module **102** may use energy stored in energy storage module **112** to generate the communication signals. In at least some examples, communication module **102** may include a switching circuit that is connected to energy storage module **112** and, with the switching circuitry, may connect energy storage module **112** to one or more of electrodes **114/114'** to generate the communication signals.

As shown in FIG. **1**, a pulse generator module **104** may be electrically connected to one or more of electrodes **114** and/or **114'**. Pulse generator module **104** may be configured to generate electrical stimulation pulses and deliver the electrical stimulation pulses to tissues of a patient via one or more of the electrodes **114** and/or **114'** in order to effectuate one or more electrical stimulation therapies. Each electrical stimulation pulse may have a pulse amplitude and a pulse width.

Electrical stimulation pulses as used herein are meant to encompass any electrical signals that may be delivered to tissue of a patient for purposes of treatment of any type of disease or abnormality. For example, when used to treat heart disease, the pulse generator module **104** may generate electrical stimulation pacing pulses for capturing the heart of the patient, i.e. causing the heart to contract in response to the delivered electrical stimulation pulse. In some of these cases, LCP **100** may vary the rate at which pulse generator module **104** generates the electrical stimulation pulses, for example in rate adaptive pacing. In other embodiments, the electrical stimulation pulses may include defibrillation/cardioversion pulses for shocking the heart out of fibrillation or into a normal heart rhythm. In yet other embodiments, the electrical stimulation pulses may include anti-tachycardia pacing (ATP) pulses. It should be understood that these are just some examples. When used to treat other ailments, the pulse generator module **104** may generate electrical stimulation pulses suitable for neurostimulation therapy or the like.

Pulse generator module **104** may include one or more capacitor elements and/or other charge storage devices to aid in generating and delivering appropriate electrical stimulation pulses. In at least some embodiments, pulse generator module **104** may use energy stored in energy storage module **112** to generate the electrical stimulation pulses. In some particular embodiments, pulse generator module **104** may include a switching circuit that is connected to energy storage module **112** and may connect energy storage module **112** to one or more of electrodes **114/114'** to generate electrical stimulation pulses.

LCP **100** may include an electrical sensing module **106**. Electrical sensing module **106** may be configured to sense intrinsic cardiac electrical signals conducted from electrodes **114** and/or **114'** to electrical sensing module **106**. For example, electrical sensing module **106** may be electrically

connected to one or more electrodes **114** and/or **114'** and electrical sensing module **106** may be configured to receive cardiac electrical signals conducted through electrodes **114** and/or **114'** via a sensor amplifier or the like. In some embodiments, the cardiac electrical signals may represent local information from the chamber in which LCP **100** is implanted. For instance, if LCP **100** is implanted within a ventricle of the heart, cardiac electrical signals sensed by LCP **100** through electrodes **114** and/or **114'** may represent ventricular cardiac electrical signals. The electrical sensing module **106** may, in some cases, be configured to identify each of a plurality of heart beats as an intrinsically initiated heart beat or a pace initiated heart beat.

Further, LCP **100** may include a mechanical sensing module **108**. Mechanical sensing module **108** may include, or be electrically connected to, various sensors, such as accelerometers, including multi-axis accelerometers such as two- or three-axis accelerometers, gyroscopes, including multi-axis gyroscopes such as two- or three-axis gyroscopes, blood pressure sensors, heart sound sensors, piezoelectric sensors, blood-oxygen sensors, and/or other sensors which measure one or more physiological parameters of the heart and/or patient. Mechanical sensing module **108**, when present, may gather signals from the sensors indicative of the various physiological parameters.

Both electrical sensing module **106** and mechanical sensing module **108** may be connected to processing module **110** and may provide signals representative of the sensed cardiac electrical signals and/or physiological signals to processing module **110**. Although described with respect to FIG. **1** as separate sensing modules, in some embodiments, electrical sensing module **106** and mechanical sensing module **108** may be combined into a single module. In at least some examples, LCP **100** may only include one of electrical sensing module **106** and mechanical sensing module **108**. In some cases, any combination of the processing module **110**, electrical sensing module **106**, mechanical sensing module **108**, communication module **102**, pulse generator module **104** and/or energy storage module may be considered a controller of the LCP **100**.

Processing module **110** (e.g., a controller) may be configured to direct the operation of LCP **100** and may, in some embodiments, be termed a controller. For example, processing module **110** may be configured to receive cardiac electrical signals from electrical sensing module **106** and/or physiological signals from mechanical sensing module **108**. Based on the received signals, processing module **110** may, for example, adjust the rate of pacing based on the activity level of the patient (e.g. rate adaptive pacing). When so provided, processing module **110** may monitor one or more physiological parameters of the patient which may indicate a need for an increased heart rate (e.g. due to increased metabolic demand) and increase the rate at which pulse generator module **104** generates electrical stimulation pulses. Determining an activity level of the patient using a motion sensor (e.g. accelerometer) of the mechanical sensing module **108** of the LCP **100** can be challenging because the motion detected by the motion sensor not only includes the activity level of the patient but also the motion of the beating heart. FIGS. **6-10** describes illustrative methods for aiding in rate responsive pacing using a motion sensor (e.g. accelerometer) in an LCP.

In some cases, the processing module **110** may determine occurrences and types of arrhythmias and other determinations such as whether LCP **100** has become dislodged. Processing module **110** may further receive information from communication module **102**. In some embodiments,

processing module **110** may additionally use such received information to determine occurrences and types of arrhythmias and/or and other determinations such as whether LCP **100** has become dislodged. In still some additional embodiments, LCP **100** may use the received information instead of the signals received from electrical sensing module **106** and/or mechanical sensing module **108**—for instance if the received information is deemed to be more accurate than the signals received from electrical sensing module **106** and/or mechanical sensing module **108** or if electrical sensing module **106** and/or mechanical sensing module **108** have been disabled or omitted from LCP **100**.

After determining an occurrence of an arrhythmia, processing module **110** may control pulse generator module **104** to generate electrical stimulation pulses in accordance with one or more electrical stimulation therapies to treat the determined arrhythmia. For example, processing module **110** may control pulse generator module **104** to generate pacing pulses with varying and/or fixed parameters (e.g., one or more of a pulse width, a pulse amplitude and/or other parameters) and in different sequences to effectuate one or more electrical stimulation therapies. As one example, in controlling pulse generator module **104** to deliver bradycardia pacing therapy, processing module **110** may control pulse generator module **104** to deliver pacing pulses having a particular pulse width and pulse amplitude designed to capture the heart of the patient at a regular interval to help prevent a metric of the heart of a patient from falling below a predetermined threshold.

For ATP therapy, processing module **110** may control pulse generator module **104** to deliver pacing pulses at a rate faster than an intrinsic heart rate of a patient in an attempt to force the heart to beat in response to the delivered pacing pulses rather than in response to intrinsic cardiac electrical signals. Once the heart is following the pacing pulses, processing module **110** may control pulse generator module **104** to reduce the rate of delivered pacing pulses down to a safer level. In Cardiac Resynchronization Therapy (CRT), processing module **110** may control pulse generator module **104** to deliver pacing pulses in coordination with another device to cause the heart to contract more efficiently. In cases where pulse generator module **104** is capable of generating defibrillation and/or cardioversion pulses for defibrillation/c cardioversion therapy, processing module **110** may control pulse generator module **104** to generate such defibrillation and/or cardioversion pulses. In some cases, processing module **110** may control pulse generator module **104** to generate electrical stimulation pulses to provide electrical stimulation therapies different than those examples described above.

Aside from controlling pulse generator module **104** to generate different types of electrical stimulation pulses and in different sequences, in some embodiments, processing module **110** may also control pulse generator module **104** to generate the various electrical stimulation pulses with varying pulse parameters. For example, each electrical stimulation pulse may have a pulse width and a pulse amplitude. Processing module **110** may control pulse generator module **104** to generate the various electrical stimulation pulses with specific pulse widths and pulse amplitudes. For example, processing module **110** may cause pulse generator module **104** to adjust the pulse width and/or the pulse amplitude of electrical stimulation pulses if the electrical stimulation pulses are not effectively capturing the heart. Such control of the specific parameters of the various electrical stimulation pulses may help LCP **100** provide more effective delivery of electrical stimulation therapy.

## 11

In some embodiments, processing module **110** may further control communication module **102** to send information to other devices. For example, processing module **110** may control communication module **102** to generate one or more communication signals for communicating with other devices of a system of devices. For instance, processing module **110** may control communication module **102** to generate communication signals in particular pulse sequences, where the specific sequences convey different information. Communication module **102** may also receive communication signals for potential action by processing module **110**.

In further embodiments, processing module **110** may control switching circuitry by which communication module **102** and pulse generator module **104** deliver communication signals and/or electrical stimulation pulses to tissue of the patient. As described above, both communication module **102** and pulse generator module **104** may include circuitry for connecting one or more electrodes **114** and **114'** to communication module **102** and/or pulse generator module **104** so those modules may deliver the communication signals and electrical stimulation pulses to tissue of the patient. The specific combination of one or more electrodes by which communication module **102** and/or pulse generator module **104** deliver communication signals and electrical stimulation pulses may influence the reception of communication signals and/or the effectiveness of electrical stimulation pulses. Although it was described that each of communication module **102** and pulse generator module **104** may include switching circuitry, in some embodiments, LCP **100** may have a single switching module connected to the communication module **102**, the pulse generator module **104**, and electrodes **114** and/or **114'**. In such embodiments, processing module **110** may control the switching module to connect modules **102/104** and electrodes **114/114'** as appropriate.

In some embodiments, processing module **110** may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of LCP **100**. By using a pre-programmed chip, processing module **110** may use less power than other programmable circuits while able to maintain basic functionality, thereby potentially increasing the battery life of LCP **100**. In other instances, processing module **110** may include a programmable microprocessor or the like. Such a programmable microprocessor may allow a user to adjust the control logic of LCP **100** after manufacture, thereby allowing for greater flexibility of LCP **100** than when using a pre-programmed chip. In still other embodiments, processing module **110** may not be a single component. For example, processing module **110** may include multiple components positioned at disparate locations within LCP **100** in order to perform the various described functions. For example, certain functions may be performed in one component of processing module **110**, while other functions are performed in a separate component of processing module **110**.

Processing module **110** may include a memory circuit and processing module **110** may store information on and read information from the memory circuit. In other embodiments, LCP **100** may include a separate memory circuit (not shown) that is in communication with processing module **110**, such that processing module **110** may read and write information to and from the separate memory circuit. The memory circuit, whether part of processing module **110** or separate

## 12

from processing module **110**, may be volatile memory, non-volatile memory, or a combination of volatile memory and non-volatile memory.

Energy storage module **112** may be a power supply and provide a power source (e.g., a power supply voltage) to LCP **100** for its operations. In some embodiments, energy storage module **112** may be a non-rechargeable lithium-based battery. In other embodiments, the non-rechargeable battery may be made from other suitable materials. In some embodiments, energy storage module **112** may include a rechargeable battery. In still other embodiments, energy storage module **112** may include other types of energy storage devices such as capacitors or super capacitors.

To implant LCP **100** inside a patient's body, an operator (e.g., a physician, clinician, etc.), may fix LCP **100** to the cardiac tissue of the patient's heart. To facilitate fixation, LCP **100** may include one or more anchors **116**. The one or more anchors **116** are shown schematically in FIG. **1**. The one or more anchors **116** may include any number of fixation or anchoring mechanisms. For example, one or more anchors **116** may include one or more pins, staples, threads, screws, helix, tines, and/or the like. In some embodiments, although not shown, one or more anchors **116** may include threads on its external surface that may run along at least a partial length of an anchor member. The threads may provide friction between the cardiac tissue and the anchor to help fix the anchor member within the cardiac tissue. In some cases, the one or more anchors **116** may include an anchor member that has a cork-screw shape that can be screwed into the cardiac tissue. In other embodiments, anchor **116** may include other structures such as barbs, spikes, or the like to facilitate engagement with the surrounding cardiac tissue.

In some examples, LCP **100** may be configured to be implanted on a patient's heart or within a chamber of the patient's heart. For instance, LCP **100** may be implanted within any of a left atrium, right atrium, left ventricle, or right ventricle of a patient's heart. By being implanted within a specific chamber, LCP **100** may be able to sense cardiac electrical signals originating or emanating from the specific chamber that other devices may not be able to sense with such resolution. Where LCP **100** is configured to be implanted on a patient's heart, LCP **100** may be configured to be implanted on or adjacent to one of the chambers of the heart, or on or adjacent to a path along which intrinsically generated cardiac electrical signals generally follow. In these examples, LCP **100** may also have an enhanced ability to sense localized intrinsic cardiac electrical signals and deliver localized electrical stimulation therapy. In embodiments where LCP **100** includes an accelerometer, LCP **100** may additionally be able to sense the motion of the cardiac wall to which LCP **100** is attached.

FIG. **2** depicts an embodiment of another device, medical device (MD) **200**, which may operate to sense physiological signals and parameters and deliver one or more types of electrical stimulation therapy to tissues of the patient. In the embodiment shown, MD **200** may include a communication module **202**, a pulse generator module **204**, an electrical sensing module **206**, a mechanical sensing module **208**, a processing module **210**, and an energy storage module **218**. Each of modules **202**, **204**, **206**, **208**, and **210** may be similar to and/or different than modules **102**, **104**, **106**, **108**, and **110** of LCP **100** in one or more manners. Additionally, energy storage module **218** may be similar to and/or different than energy storage module **112** of LCP **100** in one or more manners. However, in some embodiments, MD **200** may have a larger volume within housing **220** than a volume of

LCP 100. In such embodiments, MD 200 may include a larger energy storage module 218 and/or a larger processing module 210 capable of handling more complex operations than processing module 110 of LCP 100.

While MD 200 may be another leadless device such as shown in FIG. 1, in some instances MD 200 may include leads, such as leads 212. Leads 212 may include electrical wires that conduct electrical signals between electrodes 214 and one or more modules located within housing 220. In some cases, leads 212 may be connected to and extend away from housing 220 of MD 200. In some embodiments, leads 212 may be implanted on, within, or adjacent to a heart of a patient. Leads 212 may contain one or more electrodes 214 positioned at various locations on leads 212 and various distances from housing 220. Some leads 212 may only include a single electrode 214, while other leads 212 may include multiple electrodes 214. Generally, electrodes 214 may be positioned on leads 212 such that when leads 212 are implanted within the patient, one or more of the electrodes 214 are positioned to perform a desired function. In some cases, the one or more of the electrodes 214 may be in contact with the patient's cardiac tissue. In other cases, the one or more of the electrodes 214 may be positioned subcutaneously but adjacent the patient's heart.

MD 200 may also include one or more electrodes 214 not disposed on a lead 212. For example, one or more electrodes 214 may be connected directly to housing 220.

The electrodes 214 may conduct intrinsically generated electrical cardiac signals to leads 212. Leads 212 may, in turn, conduct the received electrical cardiac signals to one or more of the modules 202, 204, 206, and 208 of MD 200.

In some cases, MD 200 may generate electrical stimulation signals (e.g., having a signal width and a signal amplitude, such as a pulse width and a pulse amplitude), and leads 212 may conduct the generated electrical stimulation signals to electrodes 214. Electrodes 214 may then conduct the electrical stimulation signals to the cardiac tissue of the patient (either directly or indirectly).

Leads 212, in some embodiments, may additionally contain one or more sensors, such as accelerometers, blood pressure sensors, heart sound sensors, blood-oxygen sensors, and/or other sensors which are configured to measure one or more physiological parameters of the heart and/or patient. In such embodiments, mechanical sensing module 208 may be in electrical communication with leads 212 and may receive signals generated from such sensors.

While not required, in some embodiments MD 200 may be an implantable medical device. In such embodiments, housing 220 of MD 200 may be implanted in, for example, a transthoracic region of the patient. Housing 220 may generally include any of a number of known materials that are safe for implantation in a human body and may, when implanted, hermetically seal the various components of MD 200 from fluids and tissues of the patient's body. In such embodiments, leads 212 may be implanted at one or more various locations within the patient, such as within the heart of the patient, adjacent to the heart of the patient, adjacent to the spine of the patient, or any other desired location.

In some embodiments, MD 200 may be an implantable cardiac pacemaker (ICP). In these embodiments, MD 200 may have one or more leads, for example leads 212, which are implanted on or within the patient's heart. The one or more leads 212 may include one or more electrodes 214 that are in contact with cardiac tissue and/or blood of the patient's heart. MD 200 may be configured to sense intrinsically generated cardiac electrical signals and determine, for example, one or more cardiac arrhythmias based on

analysis of the sensed signals. MD 200 may be configured to deliver CRT, ATP therapy, bradycardia therapy, and/or other therapy types via leads 212 implanted within the heart. In some embodiments, MD 200 may additionally be configured to provide defibrillation/cardioversion therapy.

In some instances, MD 200 may be an implantable cardioverter-defibrillator (ICD). In such embodiments, MD 200 may include one or more leads implanted within a patient's heart. MD 200 may also be configured to sense electrical cardiac signals, determine occurrences of tachyarrhythmias based on the sensed electrical cardiac signals, and deliver defibrillation and/or cardioversion therapy in response to determining an occurrence of a tachyarrhythmia (for example by delivering defibrillation and/or cardioversion pulses to the heart of the patient). In other embodiments, MD 200 may be a subcutaneous implantable cardioverter-defibrillator (SICD). In embodiments where MD 200 is an SICD, one of leads 212 may be a subcutaneously implanted lead. In at least some embodiments where MD 200 is an SICD, MD 200 may include only a single lead which is implanted subcutaneously but outside of the chest cavity, however this is not required.

In some embodiments, MD 200 may not be an implantable medical device. Rather, MD 200 may be a device external to the patient's body, and electrodes 214 may be skin-electrodes that are placed on a patient's body. In such embodiments, MD 200 may be able to sense surface electrical signals (e.g. electrical cardiac signals that are generated by the heart or electrical signals generated by a device implanted within a patient's body and conducted through the body to the skin). MD 200 may further be configured to deliver various types of electrical stimulation therapy, including, for example, defibrillation therapy via skin-electrodes 214.

FIG. 3 illustrates an embodiment of a medical device system and a communication pathway through which multiple medical devices 100a, 100b, 306, and/or 310 of the medical device system may communicate. In the embodiment shown, medical device system 300 may include a first LCP 100a and a second LCP 100b, external medical device 306, and other sensors/devices 310.

External device 306 may be a device disposed external to a patient's body, as described previously with respect to MD 200. In at least some examples, external device 306 may represent an external support device such as a device programmer, as will be described in more detail below.

Other sensors/devices 310 may be any of the devices described previously with respect to MD 200, such as ICPs, ICDs, and SICDs. Other sensors/devices 310 may also include various diagnostic sensors that gather information about the patient, such as accelerometers, blood pressure sensors, or the like. In some cases, other sensors/devices 310 may include an external programmer device that may be used to program one or more devices of system 300.

Various devices of system 300 may communicate via communication pathway 308. For example, LCPs 100a and/or 100b may sense intrinsic cardiac electrical signals and may communicate such signals to one or more other devices 100a/100b, 306, and 310 of system 300 via communication pathway 308. In one embodiment, one or more of devices 100a/100b may receive such signals and, based on the received signals, determine an occurrence of an arrhythmia. In some cases, device or devices 100a/100b may communicate such determinations to one or more other devices 306 and 310 of system 300. In some cases, one or more of devices 100a/100b, 306, and 310 of system 300 may take action based on the communicated determination of an

arrhythmia, such as by delivering a suitable electrical stimulation to the heart of the patient. One or more of devices **100a/100b**, **306**, and **310** of system **300** may additionally communicate command or response messages via communication pathway **308**. The command messages may cause a receiving device to take a particular action whereas response messages may include requested information or a confirmation that a receiving device did, in fact, receive a communicated message or data.

It is contemplated that the various devices of system **300** may communicate via pathway **308** using RF signals, inductive coupling, optical signals, acoustic signals, or any other signals suitable for communication. Additionally, in at least some embodiments, the various devices of system **300** may communicate via pathway **308** using multiple signal types. For instance, other sensors/device **310** may communicate with external device **306** using a first signal type (e.g. RF communication) but communicate with LCPs **100a/100b** using a second signal type (e.g. conducted communication). Further, in some embodiments, communication between devices may be limited. For instance, as described above, in some embodiments, LCPs **100a/100b** may communicate with external device **306** only through other sensors/devices **310**, where LCPs **100a/100b** may send signals to other sensors/devices **310**, and other sensors/devices **310** relay the received signals to external device **306**.

In some cases, the various devices of system **300** may communicate via pathway **308** using conducted communication signals. Accordingly, devices of system **300** may have components that allow for such conducted communication. For instance, the devices of system **300** may be configured to transmit conducted communication signals (e.g. a voltage and/or current waveform punctuated with current and/or voltage pulses, referred herein as electrical communication pulses) into the patient's body via one or more electrodes of a transmitting device, and may receive the conducted communication signals via one or more electrodes of a receiving device. The patient's body may "conduct" the conducted communication signals from the one or more electrodes of the transmitting device to the electrodes of the receiving device in the system **300**. In such embodiments, the delivered conducted communication signals may differ from pacing pulses, defibrillation and/or cardioversion pulses, or other electrical stimulation therapy signals. For example, the devices of system **300** may deliver electrical communication pulses at an amplitude/pulse width that is sub-threshold. That is, the communication pulses have an amplitude/pulse width designed to not capture the heart. In some cases, the amplitude/pulse width of the delivered electrical communication pulses may be above the capture threshold of the heart, but may be delivered during a refractory period of the heart and/or may be incorporated in or modulated onto a pacing pulse, if desired.

Additionally, unlike normal electrical stimulation therapy pulses, the electrical communication pulses may be delivered in specific sequences which convey information to receiving devices. For instance, delivered electrical communication pulses may be modulated in any suitable manner to encode communicated information. In some cases, the communication pulses may be pulse width modulated and/or amplitude modulated. Alternatively, or in addition, the time between pulses may be modulated to encode desired information. In some cases, a predefined sequence of communication pulses may represent a corresponding symbol (e.g. a logic "1" symbol, a logic "0" symbol, an ATP therapy trigger symbol, etc.). In some cases, conducted communication

pulses may be voltage pulses, current pulses, biphasic voltage pulses, biphasic current pulses, or any other suitable electrical pulse as desired.

FIG. **4** depicts an illustrative medical device system **400**. For example, system **400** may include multiple devices that are implanted within a patient and are configured to sense physiological signals, determine occurrences of cardiac arrhythmias, and deliver electrical stimulation to treat detected cardiac arrhythmias. In some embodiments, the devices of system **400** may be configured to determine occurrences of dislodgment of one or more devices of system **400**. In FIG. **4**, an LCP **100** is shown fixed to the interior of the right ventricle of the heart **410**, and a pulse generator **406** is shown coupled to a lead **412** having one or more electrodes **408a-408c**. In some cases, pulse generator **406** may be part of a subcutaneous implantable cardioverter-defibrillator (SICD), and the one or more electrodes **408a-408c** may be positioned subcutaneously adjacent the heart. LCP **100** may communicate with the SICD, such as via communication pathway **308**. The locations of LCP **100**, pulse generator **406**, lead **412**, and electrodes **408a-c** depicted in FIG. **4** are just exemplary. In other embodiments of system **400**, LCP **100** may be positioned in the left ventricle, right atrium, or left atrium of the heart, as desired. In still other embodiments, LCP **100** may be implanted externally adjacent to heart **410** or even remote from heart **410**.

Medical device system **400** may also include external support device **420**. External support device **420** can be used to perform functions such as device identification, device programming and/or transfer of real-time and/or stored data between devices using one or more of the communication techniques described herein, or other functions involving communication with one or more devices of system **400**. As one example, communication between external support device **420** and pulse generator **406** can be performed via a wireless mode, and communication between pulse generator **406** and LCP **100** can be performed via a conducted communication mode. In some embodiments, communication between LCP **100** and external support device **420** is accomplished by sending communication information through pulse generator **406**. However, in other embodiments, communication between the LCP **100** and external support device **420** may be via a communication module.

FIG. **4** only illustrates one example embodiment of a medical device system that may be configured to operate according to techniques disclosed herein. Other example medical device systems may include additional or different medical devices and/or configurations. For instance, other medical device systems that are suitable to operate according to techniques disclosed herein may include additional LCPs implanted within the heart. Another example medical device system may include a plurality of LCPs with or without other devices such as pulse generator **406**, with at least one LCP capable of delivering defibrillation therapy. Still another example may include one or more LCPs implanted along with a transvenous pacemaker and with or without an implanted SICD. In yet other embodiments, the configuration or placement of the medical devices, leads, and/or electrodes may be different from those depicted in FIG. **4**. Accordingly, it should be recognized that numerous other medical device systems, different from system **400** depicted in FIG. **4**, may be operated in accordance with techniques disclosed herein. As such, the embodiment shown in FIG. **4** should not be viewed as limiting in any way.

Implantable medical devices, such as LCP **100**, often have an energy storage module **112** with a limited power capacity.

The power capacity of the energy storage module **112** often dictates the useful life expectancy of the implantable medical device. In many cases, it is the pacing stimulation pulses delivered by the implantable medical device that dominate the energy consumption from the energy storage module **112**. As such, increasing the energy efficiency of the pacing stimulation pulses can increase the longevity of the energy storage module **112** and thus the implantable medical device, and/or may reduce the size (e.g., physical size and/or storage size) of the energy storage module **112** and thus reduce the size of the implantable medical device.

In some cases, implantable medical device may include a linear power regulator to convert the battery voltage produced by the energy storage module **112** (e.g. battery voltage) to another voltage used by the implantable medical device. For example, in some cases, an implantable medical device may have a battery voltage of 5 volts, but may deliver pacing pulses at a pacing amplitude of 2.5 volts. A linear power regulator may convert the 5 Volt battery voltage to the 2.5 volts uses in generating the pacing pulses. For a linear power regulator, the maximum efficiency of this conversion may be the ratio of the output voltage (2.5V) to the input voltage (5V), or in this case 50%. The conversion efficiency of other circuits for converting a battery voltage to another voltage are also less than idea. To overcome this inefficiency, it is contemplated that the pacing pulse amplitude may be set at or near the battery voltage, and the pulse width may be adjusted until pacing pulses are produced that reliably capture the heart.

FIG. **5** depicts a schematic flow diagram for an illustrative method **150** of pacing a heart with an LCP, such as LCP **100** of FIG. **1**. The illustrative method **150** includes identifying **152** a capture threshold for a pacing stimulation pulse delivered to a patient's heart, such as through two or more of the electrodes **114** and/or **114'** of the LCP **100**. The "capture threshold" may be identified by varying the pulse amplitude and/or pulse width until a stimulation pulse is found that just captures the heart.

The method **150** may further include delivering **154** a pacing stimulation pulse having a value for a first pacing pulse parameter (e.g., a pulse amplitude, a pulse width, and/or other parameter) and a value for a second pacing pulse parameter (e.g., a pulse amplitude, a pulse width, and/or other parameter) that are based, at least in part, on the identified capture threshold. In one example, the delivered pacing stimulation pulse may have a first pacing pulse parameter (pulse amplitude) and a second pacing pulse parameter (pulse width) that correspond to the capture threshold. In another example, the delivered pacing stimulation pulse may have a first pacing pulse parameter (pulse amplitude) and/or a second pacing pulse parameter (pulse width) that is a multiple of the parameters that correspond to the capture threshold, thereby providing a capture margin beyond the identified capture threshold. In another example, the delivered pacing stimulation pulse may have a first pacing pulse parameter (pulse amplitude) and a second pacing pulse parameter (pulse width) that is derived from a strength-duration curve that provides a capture margin beyond the identified capture threshold. These are just examples. In some cases, the pacing stimulation pulse may be delivered to a patient's heart from LCP **100** through the electrodes **114** and/or **144'** in response to a determination by the processing module **110** that a pacing stimulation pulse is needed or is to be initiated.

FIG. **6** depicts a schematic flow diagram of an illustrative method **160** for identifying capture threshold values. The illustrative method **160** includes setting **162** a first pacing

pulse parameter to a fixed value (e.g., a fixed first value). In one example, the first pacing pulse parameter may be a pulse amplitude of the pacing stimulation pulse, and in some cases the fixed value may set at the battery voltage of the energy storage module **112** of LCP **100**. In some cases, the first fixed value may be considered "fixed" for at least a period of time.

Once the first pacing pulse parameter is set to the fixed value, the illustrative method **160** delivers **164** one or more pacing stimulation pulses to a patient's heart. In one example, the pacing stimulation pulses may be initiated by the processing module **110** of LCP **100**, generated by the pulse generator module **104**, and delivered through one or more of the electrodes **114** and/or **114'**. However, other pacing stimulation pulse delivery techniques may be utilized. While maintaining the first pacing pulse parameter at the fixed value, the illustrative method **160** may vary **166** the value of a second pacing pulse parameter (e.g. pulse width). In some cases, the value of the second pacing pulse parameter may be varied over different pacing pulses during a capture threshold test until the patient's heart is captured (e.g., as identified by the electrical sensing module **106** and/or the processing module **110**). The value of the second pacing pulse parameter may be varied in any manner including, but not limited to, varying the value of the second pacing pulse parameter on sequential pacing stimulation pulses of a group of pacing stimulation pulses, providing a first group of pacing stimulation pulses with a first value of the second pacing pulse parameter and then provide a next group (e.g., second or further group) of pacing stimulation pulses with a second value of the second pacing pulse parameter, and/or in any other suitable manner. Alternatively, the first pacing pulse parameter may be a pulse width of the pacing stimulation pulse and the pulse amplitude may be varied for two or more pacing stimulation pulses.

Once a capture threshold is identified from delivering pacing stimulation pulses, the illustrative method **160** may include identifying **168** a capture value for the second pacing pulse parameter. The capture value may correspond to the value of the second pacing pulse parameter used when the capture threshold is identified. In one example, where the second pacing pulse parameter is a pulse width, a value (e.g., a length of time) of the pulse width may be varied during the delivery of the one or more pacing stimulation pulses to identify a capture pulse width that corresponds to the capture threshold for the set fixed value of the first pacing pulse parameter (e.g., a set pulse amplitude). After identifying the capture threshold (e.g., the capture pulse width and the set pulse amplitude, or other values of the first and second pacing pulse parameters), the LCP **100** may deliver, via electrodes **114** and/or **114'**, one or more pacing pulses having values for the first pacing pulse parameter and the second pacing pulse parameter that is equal to or greater than the fixed value of the first pacing pulse parameter and/or equal to or greater than the capture value of the second pacing pulse parameter (e.g., see the delivering step **154** of method **150** in FIG. **5**).

In some cases, the processing module **110** of the LCP **100** may initiate identifying and/or may identify a capture threshold for a pacing pulse stimulation. In some case, the processing module **110** may initiate identifying and/or may identify a capture threshold at predetermined time intervals, after an identified event, after a patient changes position or posture, after a patient changes an activity level, and/or at one or more other times.

FIG. **7** depicts an illustrative strength-duration curve **170** with pulse duration (e.g., milliseconds (ms)) along the X-axis and pulse amplitude along the Y-axis. For all com-

binations of X values (e.g., pulse duration) and Y values (e.g., pulse amplitude) of a pacing stimulation pulse that fall on a particular strength-duration curve, a same or substantially the same stimulation effectiveness is provided by the pacing stimulation pulse to a patient's heart. As shown in the example of FIG. 7, a pacing stimulation pulse at point A on the strength-duration curve 170 has a higher value for the first pacing pulse parameter (e.g., pace amplitude) and a lower value for the second pacing pulse parameter (e.g., pulse width) relative to the value of the first pacing pulse parameter and the value of the second pacing pulse parameter for a pacing stimulation pulse at point B. However, each of the pacing pulse parameter sets at point A and point B may provide the same or substantially the same stimulation effectiveness to the patient's heart (e.g. both will capture the heart similarly).

In some cases, one or more strength duration curves may be saved in a memory of the LCP 100 (e.g., memory of the processing module 110 and/or other memory) and/or in memory with which the LCP 100 may be in communication. In some cases, a family of strength-duration curves may be stored. The family of strength-duration curves may be based on the particular patient at hand, or on a population of patients. An illustrative family of strength-duration curves are shown in FIG. 8. The LCP 100 may use an identified capture threshold for the particular patient, as determined through a capture threshold test performed by the implanted LCP 100, to identify a particular one of the family of strength-duration curve that corresponds to the capture threshold for the particular patient. Once identified, the LCP may fix the pulse amplitude (e.g. at the battery voltage) and then pick the "nth" strength-duration curve to the right to identify the pulse width that provides an appropriate capture margin. The LCP may then pace the patient's heart using pacing pulses that have the fixed pulse amplitude (e.g. the battery voltage) and the pulse width that provides the appropriate capture margin.

In some cases, the LCP 100 may use one or more strength duration curves to adjust a value of a first pacing pulse parameter and/or a value of a second pacing pulse parameter while maintaining a stimulation effectiveness of the pacing pulses. In the example of FIG. 7, point A may represent a pacing stimulation pulse at which a capture was identified and thus, the stimulation effectiveness at point A, and along the strength-duration curve 170, may be considered the capture threshold. In some cases, the processing module 110 may determine that it is more power efficient to operate at a lower value of the first pacing pulse parameter and adjust the value of the second pacing pulse parameter to a value associated with the lower value of the first pacing pulse parameter along the strength-duration curve 170 (e.g., at point B on the strength-duration curve 170). This may result in more efficiently provide pacing stimulation pulses while maintaining a stimulation effectiveness applied to the patient's heart by the pacing stimulation pulses. In some cases, a capture margin may be applied to the first pacing pulse parameter and/or the second pacing pulse parameter, as desired.

In one example, the processing module 110 may set (e.g., fix) the value of the first pacing pulse parameter to be equal to a power supply voltage provide by the energy storage module 112, and may identify the pulse width at the capture threshold, and thus the strength-duration curve 170 that is associated with the capture threshold (e.g., where the strength-duration curve may be stored in memory associated with the LCP 100). When the energy storage module 112 is a battery and the power supply voltage is the voltage of the

battery, the voltage of the battery may decay over time. As a result, the value of the first pacing pulse parameter may also decay over time in proportion to the battery voltage decay. To account for the potential decay of the value of the first pacing pulse parameter, the processing module 110 may track the battery voltage, adjust the value of the first pacing pulse parameter as the battery voltage changes over time, and adjust a value of the second pacing pulse parameter (e.g. pacing pulse width) along the identified strength-duration curve 170 to points that correspond to the adjusted value of the first pacing pulse parameter to provide pacing stimulation pulse that provide the same or similar stimulation effectiveness. In some cases, a capture margin is applied to the second pacing pulse parameter to help ensure reliable capture of the heart going forward.

FIG. 8 depicts a plurality of strength-duration curves. As referred to above a family of strength-duration curves (e.g., the five strength-duration curves 170, 172, 174, 176, 178 depicted in FIG. 8) may be saved in a memory of the LCP 100 (e.g., memory of the processing module 110 and/or other memory) and/or in memory with which the LCP 100 may be in communication. In some cases, the LCP 100 storing the family of strength-duration curves may facilitate the LCP 100 (e.g., the processing module 110) provide pacing stimulation pulses in accordance with a received or identified capture margin. For example, a capture margin may correspond to a percentage offset of the capture threshold. When so provided, the capture margin may be higher when the capture threshold is higher. In another example, the capture margin may correspond to a fixed offset from the capture threshold. In yet another example, the capture margin may be selected by moving "n" strength-duration curve to the right in FIG. 8, and then use the pulse amplitude and/or pulse width dictated by that strength-duration curve. These are just some examples.

In FIG. 8, the strength-duration curve 170 may be considered to be associated with the capture threshold of the patient. That is the capture threshold identified via a capture threshold test falls along strength-duration curve 170, such as at point A. The pacing stimulation pulses associated with each of the strength-duration curves 172, 174, 176, and 178 to the right of the strength-duration curve 170 may provide a capture margin over the pacing stimulation pulses provided in accordance with the strength-duration curve 170. In one example, the pacing stimulation pulses associated with each sequential strength duration curve 172, 124, 126 and 178 may provide one percent (1%) more, two percent (2%) more, three percent (3%) more, five percent (5%) more, ten percent (10%) more, twenty percent (20%) more, or any other suitable amount more pulse width than the pulse width provided by the pacing stimulation pulse associated with a strength duration curve 170. In another example, the pacing stimulation pulses associated with each sequential strength duration curve 172, 124, 126 and 178 may provide one percent (1%) more, two percent (2%) more, three percent (3%) more, five percent (5%) more, ten percent (10%) more, twenty percent (20%) more, or any other suitable amount more pulse amplitude than the pulse amplitude provided by the pacing stimulation pulse associated with a strength duration curve 170. In yet another example, the pacing stimulation pulses associated with each sequential strength-duration curve 172, 124, 126 and 178 may consume one percent (1%) more, two percent (2%) more, three percent (3%) more, five percent (5%) more, ten percent (10%) more, twenty percent (20%) more, or any other suitable amount of more power from the energy storage module 112 than the amount of power drawn by the pacing stimulation pulses

associated with a strength duration curve **170**. In another example, the pacing stimulation pulses associated with each sequential strength duration curve **172**, **124**, **126** and **178** may provide one percent (1%) more, two percent (2%) more, three percent (3%) more, five percent (5%) more, ten percent (10%) more, twenty percent (20%) more, or any other suitable amount more stimulation amount than the stimulation amount provided by the pacing stimulation pulse associated with a strength duration curve **170**. These are just examples. Moreover, rather than a linear progression from one strength-duration curve **172**, **124**, **126** and **178** to the next, it is contemplated that there may be a non-linear progression such as a step-wise progression, an exponential progression, a logarithmic progression, and/or any other suitable progression as desired.

In some cases, the processing module **110** of the LCP **100** may select a stored strength-duration curve based, at least in part, on an identified capture threshold and a predetermined capture margin and/or a capture margin received from a physician. In some cases, a capture threshold determined by a capture threshold test performed by the LCP **100** may not align directly with a stored strength-duration curve. In such cases, processing module **110** may select (e.g., automatically or upon selection and/or approval by a physician) a strength-duration curve that is closest to the capture threshold. Once the processing module **110** of the LCP has selected a strength-duration curve **170** associated with the capture threshold, the processing module **110** may identify a further strength-duration curve associated with the predetermined or received capture margin. For example, a capture margin may correspond to the “nth” strength-duration curve to the right of the strength-duration curve that is closest to the capture threshold.

In an example, the LCP **100** may fix the pulse amplitude (e.g. at the battery voltage) and then perform a capture threshold test by varying pulse amplitude. In FIG. **8**, this may correspond to point A along the strength-duration curve **170**. The LCP **100** may then pick the “nth” strength-duration curve to the right to identify the pulse width that provides an appropriate capture margin. For example, the LCP **100** may pick the first (e.g. n=1) strength-duration curve to the right **172**, and for the fixed pulse amplitude find a new pulse width at operating point C. Operating point C provides a desired pacing margin to help ensure reliable pacing going forward.

In another example, the LCP **100** may fix the pulse amplitude (e.g. at the battery voltage) and then perform a capture threshold test by varying pulse amplitude. In FIG. **8**, this may correspond to point B along the strength-duration curve **170**. The LCP **100** may then pick the “nth” strength-duration curve to the right to identify the pulse width that provides an appropriate capture margin. For example, the LCP **100** may pick the first (e.g. n=1) strength-duration curve to the right **172**, and for the fixed pulse amplitude find a new pulse width at operating point D. Operating point D provides a desired pacing margin to help ensure reliable pacing going forward. As shown in FIG. **8**, points A and C have the same pulse amplitude, but have different pulse widths to provide the desired capture margin. Likewise, points B and D have the same pulse amplitude, but have different pulse widths to provide the desired capture margin.

In some cases, and once a strength-duration curve has been selected to provide the desired capture margin, and the pacing amplitude drops over time due to a decreasing battery voltage, the processing module **110** may automatically adjust the pacing pulse width of the pacing stimulation pulses in accordance with the selected strength-duration curve. For example, assume the strength-duration curve **172**

of FIG. **8** has been selected to provide the desired capture margin, and the initial pacing amplitude corresponded to point C. The processing module **110** may set the pacing pulse width to correspond to operating point C. As the battery drains over time, the pacing amplitude may drop down to point D. The processing module **110** may automatically drop the pacing pulse width over time along strength-duration curve **172** to operating point D, all along providing a desired capture margin and possibly without having to update the capture threshold.

In some cases, a physician may select a desired capture margin to use. A physician may take one or more factors into consideration when adjusting or selecting a capture margin for an LCP **100**. Some factors may include, but are not limited to, an absolute pulse amplitude margin (e.g. 2 volts), a relative pulse amplitude margin (+10%), an absolute pulse width margin (e.g. 50 ms), a relative pulse width margin (+10%), a pacing pulse energy margin (e.g. 10% more energy than at the capture threshold), a margin based on a desired lifetime of the LCP **100** and/or any other suitable margin. It is contemplated that a physician may select the capture margin using a user interface, such as user interface **180** shown in FIG. **9**.

In one example, the capture margin may be related to the estimated life (e.g., duration) of the LCP **100**. As such, a physician may be given an opportunity to select a Power Efficiency Value from a user interface **180** such as shown in FIG. **9**. Based on the Power Efficiency Value selected, an appropriate capture margin may be selected at which to use when providing pacing stimulation pulses. In some cases, a pulse amplitude/pulse width combination may be selected to achieve the selected Power Efficiency Value. In some cases, the particular pulse amplitude and/or pulse width may not be reported to the physician. Instead, the pulse amplitude and/or pulse width may be optimized to reduce the overall power consumption of the LCP **100**. For example, to minimize the energy consumed in converting a battery voltage to a different pacing pulse amplitude, the pulse amplitude may be set equal to the battery voltage, and the pulse width may be adjusted to achieve the desired capture margin. The capture margin may be dependent on the Power Efficiency Value selected by the physician.

The user interface **180** may be part of a remote device (e.g., external device **360**, external support device **420**, and/or a different remote device) that may be in communication with the LCP **100** over a network (e.g., communication pathway **308**). Alternatively, or in addition, the user interface **180** may be located in or on a personal computer, a laptop computer, a tablet computer, a mobile phone, a smart phone, and/or other computing device, wherein the selected value may be communicated to the LCP **100**.

As can be seen, the user interface **180** may include a Power Efficiency Value selector **182**. In the example shown, the Power Efficiency Value selector **182** may be a slide bar that may be slid between a minimum (min) value and a maximum (max) value. Additionally or alternatively, the Power Efficiency Value selector **182** may allow a user to select a specific value in a range of values, and the values may be for a generic range (e.g., 0-10, 0-100, 14-29, and so on), may be associated with an estimated life of the LCP **100** (e.g., in years), may be associated with a capture margin percent over a capture threshold, and/or may be associated with one or more other values. In some cases, the user interface **180** may include an indicator **184** (e.g., a dynamic indicator) of an estimated life for the LCP **100** based on (e.g., that changes with) a selected Power Efficiency Value. In one example, as a higher capture margin is selected via

the Power Efficiency Value selector **182**, the shorter the duration of the expected life remaining for the LCP **100**.

FIG. **10** is a flow diagram of an illustrative method **500** of setting values for parameters of a pacing stimulation pulse that may be related to an identified capture threshold. The method **500** may include the processing module **110** of an LCP **100** setting **502** a pace amplitude (note, pulse amplitude and pace amplitude may be used interchangeably herein) to a fixed pace amplitude. In one example, the fixed pace amplitude may be a power supply voltage (e.g. battery voltage) of an energy storage module **112**, a percentage of the power supply voltage, and/or other voltage. Then, while providing pacing stimulation pulses to a patient via the electrodes **114**, **114'**, the method **500** may include adjusting **504** a pulse width of the pacing stimulation pulses until a capture threshold has been identified, and then selecting **506** a threshold strength duration curve (e.g., curve **170** in FIGS. **7** and **8**) corresponding to the capture threshold.

As an alternative to setting the pace amplitude of the pacing stimulation pulses to a fixed pace amplitude and adjusting the pulse width of the pacing stimulation pulses to identify a capture threshold as in steps **502** and **504**, the processing module **110** may be configured to set the pulse width of the pacing stimulation pulses to a fixed pulse width and adjust the pace amplitude of the pacing stimulation pulses to identify a capture threshold.

At step **508**, the processing module **110** may determine whether a capture margin has been received, and if no capture margin has been received, the processing module **110** may set **510** electrical stimulation pulse settings based, at least in part, on the strength-duration curve corresponding to the capture threshold and a default capture margin if present. This may include automatically selecting a capture margin strength duration curve based, at least in part, on the default capture margin and the strength-duration curve corresponding to the identified capture threshold. Then, the processing module **110** may set **510** electrical stimulation pulse settings based, at least in part, on the selected margin strength-duration curve.

In instances when a capture margin has been received, such as from a physician, the processing module **110** may set electrical stimulation pulse settings based, at least in part, on the strength-duration curve corresponding to the capture threshold and the received capture margin. This may include automatically selecting **512** a capture margin strength duration curve based, at least in part, on the received capture margin and the strength-duration curve corresponding to the identified capture threshold. Then, the processing module **110** may set **514** electrical stimulation pulse settings based, at least in part, on the selected margin strength-duration curve.

FIG. **11** is a flow diagram of an illustrative method **600** of setting values for parameters of a pacing stimulation pulse that may be related to a capture threshold. In the illustrative method **600**, the processing module **110** may identify **602** a fixed pace amplitude. In one example, the fixed pace amplitude may be a power supply voltage (e.g. battery voltage) of an energy storage module **112**, a percentage of the power supply voltage, and/or other voltage. The processing module **110** may set **604** a pace amplitude of a pacing stimulation pulse to a fraction of the identified fixed pace. In one example, the set pace amplitude may be a fraction of a power supply voltage of the energy storage module **112**, and may be set based on a desired capture margin. In one example, if the capture margin is 2 times the capture threshold, the fraction may be set to one half and the set pacing amplitude will be one half of the identified fixed pace amplitude. Once

the pace amplitude has been set and the while the LCP **100** may be applying pacing stimulation pulses to a patient, the processing module **110** may adjust **606** a pulse width of the pacing stimulation pulses until a capture threshold is identified. Once the capture threshold has been identified and an associated pulse width at the set pulse amplitude of the pacing stimulation pulse is stored, the processing module **110** may re-set **608** the pacing stimulation pulses to have the identified fixed pace amplitude and set **610** the pacing stimulation pulses to have the pulse width corresponding to that identified at the capture threshold. The resulting pacing stimulation pulse may have parameter values that result in the desired capture margin (2×).

In some cases, the processing module **110** may identify a strength-duration curve associated with the set pacing pulse parameter values that correspond to the capture threshold and the desired capture margin (e.g., the processing module **110** may select a strength-duration curve that may be the closest curve to the set pacing pulse parameter values) and adjust the pulse width over time as the pace amplitude changes over time due to power supply voltage decay or the like.

FIG. **12** is a flow diagram of an illustrative method **700** of adjusting, over time, a set pace amplitude for pacing stimulation pulses. The illustrative method **700** may be implemented by the processing module **110** of the LCP **100** at initial set up of the device before and/or after implantation, at pre-set intervals after initial set up of the implanted device, continuously in real-time after initial set up of the implanted device, and/or at any other time. The illustrative method **700** may include the processing module **110** determining **702** a fixed pace amplitude at which to set the pace amplitude of a pacing stimulation pulse, and determining **704** a pulse width at the fixed pace amplitude. As discussed herein, in one example, the fixed pace amplitude may correspond to the power supply voltage (e.g. battery voltage) of the energy storage module **112**, a percentage of the power supply voltage, and/or other voltage as desired. The pulse width at the fixed pace amplitude may be determined by identifying a pulse width associated with (e.g., lined up with) the fixed pace amplitude along a strength-duration curve (e.g., strength-duration curves **170**, **172**, **174**, **176**, **178** in FIG. **8** or other strength-duration curves). Once the fixed pace amplitude of the pacing stimulation pulses is determined **702** and an associated pulse width for the pacing stimulation pulses is determined **704**, the processing module **110** may adjust **706** the electrical stimulation pulse settings to the determined fixed pace amplitude and the determined pulse width.

Over time (e.g., at pre-determined time intervals or in real time), the processing module **110** may determine **708** if a bases for determining the fixed pace amplitude has changed. In one example, if the fixed pace amplitude is set to be equal to a power supply voltage from the energy storage module **112**, the processing module **110** may determine if the power supply voltage from the energy storage module **112** has changed by a predetermined amount since the fixed pace amplitude was previously determined. This determination may be made continuously at pre-determined times and/or in real-time. If the processing module **110** determines the bases for determining the fixed pace amplitude has not changed, then the processing module **110** may maintain **710** the current pacing stimulation pulse settings and continuously determine **708** if a bases for determining the fixed pace amplitude has changed. If the processing module **110** determines the bases for determining the fixed pace amplitude has changed, then the processing module **110** may return to

determining **702** a fixed pace amplitude at which to set the pace amplitude of the pacing stimulation pulses and the method **700** may be repeated.

Those skilled in the art will recognize that the present disclosure may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. For instance, as described herein, various embodiments include one or more modules described as performing various functions. However, other embodiments may include additional modules that split the described functions up over more modules than that described herein. Additionally, other embodiments may consolidate the described functions into fewer modules.

Although various features may have been described with respect to less than all embodiments, this disclosure contemplates that those features may be included on any embodiment. Further, although the embodiments described herein may have omitted some combinations of the various described features, this disclosure contemplates embodiments that include any combination of each described feature. Accordingly, departure in form and detail may be made without departing from the scope and spirit of the present disclosure as described in the appended claims.

What is claimed is:

**1.** A leadless cardiac pacemaker (LCP) for delivering pacing pulses to a heart of a patient, the LCP comprising:

a power supply for providing a power supply voltage;  
a pair of electrodes for delivering pacing pulses to the heart of the patient;

a controller operably connected to the pair of electrodes and the power supply, the controller configured to:  
identify a capture threshold by:

setting a pace amplitude to the power supply voltage;

delivering via the pair of electrodes a plurality of pacing pulses having the pace amplitude with different pulse widths to identify a capture pulse width that corresponds to the capture threshold of the heart;

deliver via the pair of electrodes a plurality of pacing pulses having the pace amplitude and a pacing pulse width that is greater than the capture pulse width by a pulse width margin.

**2.** The LCP of claim **1**, wherein the power supply comprises a battery, and the power supply voltage comprises a battery voltage provided by the battery.

**3.** The LCP of claim **2**, wherein the battery voltage, and thus the pace amplitude, decays over time.

**4.** The LCP of claim **3**, wherein the controller is configured to repeatedly identify the capture threshold.

**5.** The LCP of claim **1**, wherein the controller stores data representing one or more strength-duration curves, and the controller is configured to identify a capture threshold strength-duration curve based at least in part on the pace amplitude and the capture pulse width, and the controller is further configured to identify the pulse width margin by referencing a different one of the strength-duration curves and the pace amplitude.

**6.** The LCP of claim **5**, wherein if the power supply voltage changes, and thus the pace amplitude changes, the controller is configured to automatically adjust the pacing pulse width based at least in part on the different one of the strength-duration curves and the changed pace amplitude, without having to update the capture threshold by delivering via the pair of electrodes a plurality of pacing pulses having the changed pace amplitude and different pulse widths.

**7.** The LCP of claim **1**, wherein the controller is further configured to receive a user selectable power efficiency

value, and wherein the pulse width margin is based at least in part on the user selectable power efficiency value.

**8.** A leadless cardiac pacemaker (LCP) for delivering pacing pulses to a heart of a patient, the LCP comprising:

a pair of electrodes for delivering pacing pulses to the heart of the patient;

a controller operably connected to the pair of electrodes, the controller configured to:

identify a capture threshold by delivering via the pair of electrodes a plurality of pacing pulses while varying a first pacing pulse parameter value while leaving a second pacing pulse parameter value fixed in order to identify a capture value for the first pacing pulse parameter; and

deliver via the pair of electrodes a plurality of pacing pulses that each have the first pacing pulse parameter value at the capture value and the second pacing pulse parameter value at a capture margin above the fixed second pacing pulse parameter value.

**9.** The LCP of claim **8**, wherein the first pacing pulse parameter is pulse width and the second pacing pulse parameter is pulse amplitude.

**10.** The LCP of claim **9**, further comprising a battery that provides a battery voltage, and wherein the fixed second pacing pulse parameter value is a predetermined fraction of the battery voltage.

**11.** The LCP of claim **10**, wherein the second pacing pulse parameter value at the capture margin above the fixed second pacing pulse parameter value corresponds to the battery voltage.

**12.** The LCP of claim **8**, wherein the first pacing pulse parameter is pulse amplitude and the second pacing pulse parameter is pulse width.

**13.** The LCP of claim **8**, wherein the controller stores data representing one or more strength-duration curves, and the controller is configured to identify the capture margin based at least in part on one or more of the strength-duration curves.

**14.** A leadless cardiac pacemaker (LCP) for delivering pacing pulses to a heart of a patient, the LCP comprising:

a pair of electrodes for delivering pacing pulses to the heart of the patient;

a controller operably connected to the pair of electrodes, the controller configured to:

receive a user selectable power efficiency value from a remote device;

identify a pulse width and pulse amplitude combination that corresponds to a capture threshold;

apply a capture margin to one or more of the pulse width and pulse amplitude resulting in a pacing pulse width and a pacing pulse amplitude, wherein the capture margin is based at least in part on the user selectable power efficiency value; and

deliver pacing pulses using the pacing pulse width and the pacing pulse amplitude.

**15.** The LCP of claim **14**, wherein the controller is configured to store data representing one or more strength-duration curves, and wherein the controller is configured to identify the capture margin by indexing the user selectable power efficiency value into the data representing one or more strength-duration curves.

**16.** The LCP of claim **15**, wherein the controller is configured to receive the data representing one or more strength-duration curves from the remote device.

17. The LCP of claim 14, wherein the remote device comprises a user interface including a display, wherein a user can use the user interface to select the user selectable power efficiency value.

18. The LCP of claim 17, wherein the remote device 5 displays a slider on the display that allows the user select the user selectable power efficiency value from a range of allowable user selectable power efficiency values.

19. The LCP of claim 17, wherein the remote device displays a dynamic indicator of an expected life time of the LCP based, at least in part, on the user selectable power efficiency value. 10

20. The LCP of claim 14, further comprising a battery for providing a battery voltage, and wherein the pacing pulse amplitude is set to the battery voltage. 15

\* \* \* \* \*